Literature DB >> 22792322

The E3-ubiquitin ligase TRIM50 interacts with HDAC6 and p62, and promotes the sequestration and clearance of ubiquitinated proteins into the aggresome.

Carmela Fusco1, Lucia Micale, Mikhail Egorov, Maria Monti, Ester Valentina D'Addetta, Bartolomeo Augello, Flora Cozzolino, Alessia Calcagnì, Andrea Fontana, Roman S Polishchuk, Gerard Didelot, Alexandre Reymond, Piero Pucci, Giuseppe Merla.   

Abstract

In this study we report that, in response to proteasome inhibition, the E3-Ubiquitin ligase TRIM50 localizes to and promotes the recruitment and aggregation of polyubiquitinated proteins to the aggresome. Using Hdac6-deficient mouse embryo fibroblasts (MEF) we show that this localization is mediated by the histone deacetylase 6, HDAC6. Whereas Trim50-deficient MEFs allow pinpointing that the TRIM50 ubiquitin-ligase regulates the clearance of polyubiquitinated proteins localized to the aggresome. Finally we demonstrate that TRIM50 colocalizes, interacts with and increases the level of p62, a multifunctional adaptor protein implicated in various cellular processes including the autophagy clearance of polyubiquitinated protein aggregates. We speculate that when the proteasome activity is impaired, TRIM50 fails to drive its substrates to the proteasome-mediated degradation, and promotes their storage in the aggresome for successive clearance.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22792322      PMCID: PMC3392214          DOI: 10.1371/journal.pone.0040440

Source DB:  PubMed          Journal:  PLoS One        ISSN: 1932-6203            Impact factor:   3.240


Introduction

The ubiquitin proteasome system (UPS) is a highly conserved pathway that removes non-functional, damaged, and/or misfolded proteins from the cell. However, when the capacity of the proteasome is impaired, misfolded proteins cannot be properly cleared and they accumulate into the aggresome [1], [2], an inclusion body localized in the proximity of the microtubule-organizing centre (MTOC) [3], [4]. Microtubule-associated histone deacetylase 6 (HDAC6) mediates this process [5]. Through its ubiquitin-binding BUZ finger domain, HDAC6 binds to and facilitates the transport of polyubiquitinated misfolded proteins along microtubules to aggresome [2]. Aggresome clearance is mediated by ubiquitin-binding proteins like p62/SQSTM1 and NBR1 [6]. These adaptor proteins through their ubiquitin-binding domain (UBA) decide the fate of protein degradation either through UPS or autophagy-lysosome pathway [6], [7], [8]. Ubiquitin ligases are terminal enzyme in the process of ubiquitination, which provides specificity to the pathway by recognizing the substrates. Experimental evidences suggest that E3-Ubiquitin ligases play an important role also in the execution of autophagy [9], [10]. Therefore searching for new E3-Ubiquitin ligases involved in such processes are of interest. TRIM proteins are RING E3-Ubiquitin ligases defined by the presence of a tripartite motif consisting of a RING, one or two B-Box, and a Coiled-Coil domain involved in a variety of cellular processes, including regulation of cell cycle progression, differentiation, development, oncogenesis, and apoptosis [11], [12], [13]. TRIM50 is one of 28 hemizygous genes mapping to the region rearranged in Williams Beuren syndrome (WBS) [14], [15], a genomic disorder characterized by mental retardation and multiple dysmorphic and metabolic features [16]. TRIM50 encodes an E3-Ubiquitin ligase that self-associates to form cytoplasmic bodies in the cell, like other TRIM proteins [13], [15]. The nature and role of these bodies as well as the cellular function of TRIM50 is just beginning to emerge [15]. Here we report that TRIM50 cytoplasmic bodies are aggresome precursors. We show that during proteasome impairment TRIM50 promotes the recruitment and aggregation of polyubiquitinated proteins to the aggresome, and participates to aggresome clearance. In addition we identified two novel TRIM50 protein interactors, HDAC6 and p62, and show that TRIM50 determines the accumulation of both p62 and HDCA6 into an insoluble protein aggregate fraction.

TRIM50 bodies colocalize into aggresome by a Hdac6-dependent way.

(A) SH-SY5Y cells were stained with anti-TRIM50 antibody. (B) SH-SY5Y cells were stained with anti-TRIM50 and anti-HDAC6 antibodies. The cells were treated with 25 µM MG132 for 6 h (d,e,f). (C) Hdac6 wild type and Hdac6 deficient mouse fibroblasts were transfected with EGFP-Trim50 followed by treatment with 25 µM MG132 for 6 h where indicated, and immunostained with FK2 antibody.

Results

TRIM50 Localizes to Cytoplasmic Bodies

We previously reported that ectopically expressed TRIM50 localizes mainly into discrete cytoplasmic punctuate structures heterogeneous in size and shape, with the intact central region of the protein (B-Box and Coiled-Coil domains) indispensable for the proper localization [15]. To rule out that the observed pattern was due to TRIM50 overexpression, we showed that also the endogenous TRIM50 localizes in diffuse cytoplasmic round bodies in human neuroblastoma-derived SH-SY5Y cell lines (Figure 1A). Ectopically expressed TRIM50 cytoplasmic bodies did not associate with known cellular compartments and markers including trans- and cis-Golgi, endosomes, caveolae, vesicles, lysosomes, cytosckeletal structures, peroxisomes, stress granules, and P-bodies (Figure S1).
Figure 1

TRIM50 bodies colocalize into aggresome by a Hdac6-dependent way.

(A) SH-SY5Y cells were stained with anti-TRIM50 antibody. (B) SH-SY5Y cells were stained with anti-TRIM50 and anti-HDAC6 antibodies. The cells were treated with 25 µM MG132 for 6 h (d,e,f). (C) Hdac6 wild type and Hdac6 deficient mouse fibroblasts were transfected with EGFP-Trim50 followed by treatment with 25 µM MG132 for 6 h where indicated, and immunostained with FK2 antibody.

TRIM50 interacts with HDAC6 and p62.

(A) The interaction between TRIM50 and HDAC6 was assayed in HEK293 FLAG-TRIM50#3 cell line, treated with MG132. The cell lysates were immunoprecipitated (IP) with anti-FLAG and Immunoblot (IB) with HDAC6 antibody. Asterisk indicate IgG aspecific band. (B) Schematic representation of TRIM50 deletion mutants used, with the minimal TRIM50 interaction region. (C) The interaction between TRIM50 and p62 was assayed in FLAG-TRIM50#3 transfected with Myc-p62. The cell lysates were immunoprecipitated with anti-FLAG (left) and with anti-Myc (right) antibodies, respectively. Immunoblot were done as indicated (asterisk indicates FLAG-TRIM50 coming from the first FLAG blotting). (D) Total lysates of HEK293 cells transfected both with TRIM50 deletion mutants and Myc-p62 were immunoprecipitated with anti-FLAG and immunoblotted with anti-Myc. Using live microscopy, we showed that ectopically expressed TRIM50 cytoplasmic bodies are highly motile structures varying in size and shape that exhibit multidirectional short and fast jumping movements and able to assemble larger cytoplasmic bodies from smaller particles (Figure S2A–B, and Movie S1). To gain insight into the dynamics of TRIM50 bodies, we performed Fluorescence Recovery After Photobleaching (FRAP) [17]. Our analysis revealed that the fluorescence of a photobleached cytoplasmic body significantly recovers within the 2 min of the time-period experiment (Fig. S2C, and Movie S2). The FRAP data confirm that TRIM50 cytoplasmic bodies are dynamic, rapidly exchanging between different cytoplasmic regions, and promptly turned over.

p62 deletion mutants interacting with TRIM50.

(A) Schematic representation of p62 deletion mutants with the minimal region of interaction with TRIM50. Lysates from FLAG-TRIM50#3 expressing a number of p62 deletion mutants were immunoprecipitated with anti-FLAG and immunoblotted with anti-GFP (B) and anti-GST (C). Further characterization of TRIM50 bodies was achieved by Correlative Light-Electron Microscopy (CLEM). This analysis revealed that the fluorescent bodies corresponded to heterogeneous in morphology TRIM50-containing protein aggregates, confirming their tendency to self-associate into larger structures (Figure S2D).

TRIM50 Associates with Aggresome

We asked whether TRIM50 bodies associate with aggresome. In SH-SY5Y cells, treated with the proteasome inhibitor MG132 and stained with FK2, which recognizes polyubiquitinated proteins, endogenous TRIM50 concentrated close to a perinuclear structure whose morphology and localization resemble that of aggresome (Figure S3A, d–f). To further investigate the possible link between TRIM50 and aggresome, we used HDAC6, an established aggresome marker [18]. We found that both endogenous and transfected TRIM50 partially located with HDAC6 under proteasome inhibition (Figure 1B, d–f; Figure S3B, d–f). This cellular localization does not depend on the E3-ligase activity of the RING domain of TRIM50 as a mutant lacking the RING domain retains the ability to localize to aggresome (Figure S4A).

TRIM50 colocalizes with p62 into aggresome.

(A) SH-SY5Y cells were stained with anti-HDAC6 and with anti-p62 antibodies. The cells were treated with 25 µM MG132 for 6 h (d,e,f). (B) SH-SY5Y cells were stained with anti-TRIM50 and anti-p62 antibodies. The cells were treated with 25 µM MG132 for 6 h (d,e,f). (C) Lysates from FLAG-TRIM50#3 and FLAG#3 cell lines, treated with vehicle (–) or MG132 (+) were separated in RIPA detergent-soluble (S) and detergent insoluble (I) fractions and immunoblotting with anti-FLAG and anti-ubiquitin antibodies. (D) Lysates from MEF Trim50 cell lines with different genotype (+/+, −/−), treated with vehicle (–) or MG132 (+) were separated in RIPA detergent-soluble (S) and detergent insoluble (I) fractions, analyzed by Western Blot and immunoblotting with anti-ubiquitin antibody. In accordance with the central role of retrograde microtubule-dependent transport in the formation of aggresome, nocodazole treatment of SH-SY5Y cells prevented the localization of TRIM50 to aggresome (data not shown). In agreement we demonstrated that TRIM50 interacts with Tubulin beta 2B class IIb (Tubb2b) (NM_178012.4), a microtubules component (Figure S3C). Together these findings suggest that TRIM50 bodies may represent aggresome precursors that in response to proteasome inhibition move towards aggresome by a microtubule dependent transport.

TRIM50 promotes the accumulation of polyubiquitinated proteins into the aggresome.

(A) MEF Trim50 cell lines were stained with anti-FK2 antibody. The area, perimeter and intensity of signal of three independent experiments of each genotype were estimated using imageJ program. (B) MEF Trim50 cell lines were treated with 10 µM MG132 over night and stained with anti-FK2 antibody. The area, perimeter and intensity of signal of three independent experiments of each genotype were estimated using imageJ program. (C) MEF Trim50 cell lines were treated with 10 µM MG132 over night, incubated o and 48 h with DMEM after MG132 wash out and stained with anti-FK2 antibody. The diagram shows the percentage of aggresome-positive cells. To assess whether HDAC6 is required for the proper localization of TRIM50, we performed immunofluorescence assays in Hdac6 deficient mouse fibroblasts [19]. We found that in Hdac6 wild-type cells, Trim50 bodies localize within FK2-ubiquitin-containing aggresomes upon MG132 treatment (Figure 1C, d–f). Conversely, when MG132 was added to Hdac6 knock out cells Trim50 bodies were unable to form whole aggresome, although they still continued to partially colocalize with ubiquitinated aggregates (Figure 1C, j–l). These results indicate that HDAC6 is required for the proper localization of TRIM50 bodies and of ubiquitinated proteins within the aggresome. We then investigated whether the observed TRIM50-HDAC6 colocalization results also in their physical interaction. As no anti-TRIM50 antibodies are actually effective for immunoprecipitation assays, we generated a HEK293 cell line that stably expresses a FLAG-tagged TRIM50 (hereafter referred to as FLAG-TRIM50#3). As shown in Figure 2A, TRIM50 interacts with endogenous HDAC6; an interaction that strengthens in response to MG132 treatment (compare lane 1 to lane 2 in Figure 2A).
Figure 2

TRIM50 interacts with HDAC6 and p62.

(A) The interaction between TRIM50 and HDAC6 was assayed in HEK293 FLAG-TRIM50#3 cell line, treated with MG132. The cell lysates were immunoprecipitated (IP) with anti-FLAG and Immunoblot (IB) with HDAC6 antibody. Asterisk indicate IgG aspecific band. (B) Schematic representation of TRIM50 deletion mutants used, with the minimal TRIM50 interaction region. (C) The interaction between TRIM50 and p62 was assayed in FLAG-TRIM50#3 transfected with Myc-p62. The cell lysates were immunoprecipitated with anti-FLAG (left) and with anti-Myc (right) antibodies, respectively. Immunoblot were done as indicated (asterisk indicates FLAG-TRIM50 coming from the first FLAG blotting). (D) Total lysates of HEK293 cells transfected both with TRIM50 deletion mutants and Myc-p62 were immunoprecipitated with anti-FLAG and immunoblotted with anti-Myc.

TRIM50-related aggresome and TRIM50 itself are partially degraded through the autophagy-lysosomal pathway.

(A) FLAG-TRIM50#3 cells were treated with 20 mM NH4Cl (A) and DMSO for a period of 10 hours. Cells were lysed at the indicated time after the initiation of treatment and analysed by Western blotted using FLAG and GAPDH antibodies, respectively. The experiments were performed three times and typical results are shown. (B) Curves describing TRIM50 levels as a function of time, based on the results in panel A. The density of each band was determined by densitometer. The half-time of TRIM50 was determined by calculating the protein level at each time, normalized to the corresponding GAPDH level, to the initial amount of TRIM50 protein and compared with the control cells treated with DMSO. (C) HeLa cells overexpressing EGFP-TRIM50 were incubated in complete medium (a–c), EBSS (d–f), and DMEM supplemented with NH4Cl 20 mM for 2 h respectively and stained with an anti-FK2 antibody.

TRIM50 Interacts with p62

Proteomics assays were designed to identify novel TRIM50 partners. TRIM50 complexes were isolated by immunoprecipitation of total protein lysate from FLAG-TRIM50#3 cells and individual protein components were solved and identified by nano LC-MS/MS. Among the putative TRIM50 interactors, we focused on p62 (also known as Sequestosome 1/p62), because of its involvement in the formation of protein aggregates [20], its role as shuttling factor for the delivery of polyubiquitinated substrates to the proteasome [21], and for emerging central importance at the intersection of proteasome and autophagy pathways [22]. First we assessed whether TRIM50 and p62 self associate. FLAG-TRIM50#3 cells was transfected with a plasmid that expresses Myc-tagged p62. Total cell lysates were then immunoprecipitated with an anti-FLAG and immunoblotted with an anti-Myc specific antibody. An anti-Myc reactive band was exclusively precipitated in the presence of FLAG-TRIM50 (Figure 2C, left side). Consistently, we detected FLAG-TRIM50 in protein lysates immunoprecipitated with an anti-Myc and immunoblotted with an anti-FLAG antibody (Figure 2C, right side), substantiating the interaction between TRIM50 and p62. Next, to map the TRIM50 domain(s) involved in p62 interaction, we used a set of FLAG-TRIM50 mutants [15] (Figure 2B). Upon co-transfection with Myc-p62 and coimmunoprecipitation with an anti-FLAG, we found that both coiled coil domains of TRIM50 are required for the efficient binding of p62 (Figure 2D). Likewise, to define the p62 interaction region, we performed co-immunoprecipitation and GST pull down assays using p62 deletion mutants (Figure 3A). As reported in Figure 3B and 3C we narrowed the p62 interaction region between aminoacids 302–370, a region that includes the LC3 binding region [23].
Figure 3

p62 deletion mutants interacting with TRIM50.

(A) Schematic representation of p62 deletion mutants with the minimal region of interaction with TRIM50. Lysates from FLAG-TRIM50#3 expressing a number of p62 deletion mutants were immunoprecipitated with anti-FLAG and immunoblotted with anti-GFP (B) and anti-GST (C).

TRIM50 Promotes the Sequestration of Ubiquitinated Proteins into Aggresome and Drives the Accumulation of p62 and HDAC6

We investigated whether TRIM50 and p62 colocalize into the aggresome. First, by fluorescence microscopy we showed that p62 colocalizes with HDAC6 upon MG132 treatment (Figure 4A). Then we found a partial colocalization between endogenous p62 and TRIM50 in SH-SY5Y cells (Figure 4B, a–c), which was intensified in presence of MG132 (Figure 4B, d–f).
Figure 4

TRIM50 colocalizes with p62 into aggresome.

(A) SH-SY5Y cells were stained with anti-HDAC6 and with anti-p62 antibodies. The cells were treated with 25 µM MG132 for 6 h (d,e,f). (B) SH-SY5Y cells were stained with anti-TRIM50 and anti-p62 antibodies. The cells were treated with 25 µM MG132 for 6 h (d,e,f). (C) Lysates from FLAG-TRIM50#3 and FLAG#3 cell lines, treated with vehicle (–) or MG132 (+) were separated in RIPA detergent-soluble (S) and detergent insoluble (I) fractions and immunoblotting with anti-FLAG and anti-ubiquitin antibodies. (D) Lysates from MEF Trim50 cell lines with different genotype (+/+, −/−), treated with vehicle (–) or MG132 (+) were separated in RIPA detergent-soluble (S) and detergent insoluble (I) fractions, analyzed by Western Blot and immunoblotting with anti-ubiquitin antibody.

Next we asked whether TRIM50 has any role in the recruitment and/or accumulation of polyubiquitinated proteins to the aggresome. MG132 treatment resulted in a prominent accumulation of higher-molecular-weight species constituted by polyubiquitinated proteins in the detergent insoluble fraction as showed by immunoblot with an anti-ubiquitin antibody (Figure 4C). These data were confirmed in Trim50 deficient mouse embryo fibroblasts (kindly provided by Prof. Reymond). Depletion of endogenous Trim50 resulted in a decrease of polyubiquitinated protein levels in MG132 treated cells (compare lane 4 to 8 in Figure 4D). We then examined whether the TRIM50 depletion influences the area, perimeter, and intensity of FK2-polyubiquitinated dots. MEF Trim50−/− cells showed a significant decrease of signal intensity, compared to the wild type and heterozygous counterpart, while no significant difference was observed for the area and size of the dots (Figure 5A). Notably, MEF Trim50−/− cells treated with MG132 showed a highly significant reduction of all three parameters compared to the wild type and heterozygous mouse cell lines, respectively (Figure 5B).
Figure 5

TRIM50 promotes the accumulation of polyubiquitinated proteins into the aggresome.

(A) MEF Trim50 cell lines were stained with anti-FK2 antibody. The area, perimeter and intensity of signal of three independent experiments of each genotype were estimated using imageJ program. (B) MEF Trim50 cell lines were treated with 10 µM MG132 over night and stained with anti-FK2 antibody. The area, perimeter and intensity of signal of three independent experiments of each genotype were estimated using imageJ program. (C) MEF Trim50 cell lines were treated with 10 µM MG132 over night, incubated o and 48 h with DMEM after MG132 wash out and stained with anti-FK2 antibody. The diagram shows the percentage of aggresome-positive cells.

Since the aggregates formation is a reversible process, to explore the effect of TRIM50 on the clearance of aggresome components, we analyzed the aggresome insolvency. MG132-pretreated MEF Trim50 cells were incubated in a free-drug media for 48 h, and the FK2-aggresome positive cells were counted. Immediately after the removal of MG132, we found a significant decrease of the number of FK2-positive aggregates in Trim50−/− cells compared to the Trim50+/+ (Figure 5C). More interestingly, 48 hours after the MG132 removal we observed a significantly higher number of FK2-positive aggregates in MEF Trim50−/− compared to MEF Trim50+/+ suggesting that Trim50 is required for the clearance of polyubiquitinated proteins included within aggresome (p = 0.03, Figure 5C). Thus our analysis suggests that TRIM50 plays an active role in the sequestration of polyubiquitinated proteins in the aggresome. Finally, we assessed whether TRIM50 overexpression has any effect on protein level of the endogenous HDAC6 and p62. p62 protein enrichment was observed in both soluble and insoluble fractions upon TRIM50 overexpression in the presence of MG132 (Figure S5A–B). Likewise we observed an increase of HDAC6 protein amount in both fractions, mainly upon MG132 treatment (Figure S5C). These results demonstrate that TRIM50 promotes the accumulation of both p62 and HDCA6, particularly into detergent insoluble aggregates.

Inhibition of Lysosomal Activity Results in TRIM50 Accumulation and Increases the Number of TRIM50-positive Bodies

To evaluate the role of the autophagy in the turnover of TRIM50, we measured the amount of TRIM50 protein level in cells treated or not with the lysosomal enzyme inhibitor ammonium chloride (NH4Cl) (Figure 6A–B). Compared with DMSO treated-cells, treatment with NH4Cl resulted in about 5 fold-increases in TRIM50 levels over time. Moreover we monitored the subcellular localization of TRIM50 cytoplasmic bodies after induction and inhibition of autophagic flux. In cells treated with NH4Cl, we observed a slight but clear increase in the number of intracellular TRIM50 positive bodies (Figure 6 C). Notably, FK2 positive proteins lose their colocalization with TRIM50 bodies after the inhibition of autophagic flux. These data suggested that TRIM50 itself and TRIM50-related bodies might be mainly degraded by autophagy-lysosomal pathway.
Figure 6

TRIM50-related aggresome and TRIM50 itself are partially degraded through the autophagy-lysosomal pathway.

(A) FLAG-TRIM50#3 cells were treated with 20 mM NH4Cl (A) and DMSO for a period of 10 hours. Cells were lysed at the indicated time after the initiation of treatment and analysed by Western blotted using FLAG and GAPDH antibodies, respectively. The experiments were performed three times and typical results are shown. (B) Curves describing TRIM50 levels as a function of time, based on the results in panel A. The density of each band was determined by densitometer. The half-time of TRIM50 was determined by calculating the protein level at each time, normalized to the corresponding GAPDH level, to the initial amount of TRIM50 protein and compared with the control cells treated with DMSO. (C) HeLa cells overexpressing EGFP-TRIM50 were incubated in complete medium (a–c), EBSS (d–f), and DMEM supplemented with NH4Cl 20 mM for 2 h respectively and stained with an anti-FK2 antibody.

Discussion

In this study we showed that the E3 ubiquitin ligase TRIM50 forms highly dynamic and heterogeneous cytoplasmic bodies containing polyubiquitinated proteins. Inhibition of proteasome activity resulted in the coalescence of TRIM50 bodies into aggresome and in their colocalization with HDCA6 protein; this localization does not depend on the E3 ubiquitin ligase activity of TRIM50. Using fibroblast from Hdac6-deficient mice, we demonstrated that the TRIM50 aggresome localization is HDAC6-dependent. Importantly, in the presence of MG132, we observed that TRIM50 bodies change their shape in absence of HDAC6, becoming larger and lost the localization into the aggresome. Overall these evidences demonstrated that the TRIM50 inclusion bodies are aggresome precursors. Evidence that the TRIM50 localization is not merely artifact of overexpression comes from experiment in which the endogenous TRIM50 displayed a very similar localization to that of transfected protein (Figure 1B and S3B). Importantly this study demonstrated that TRIM50 is a novel component of and promotes the accumulation of ubiquitinated substrates to aggresome. Moreover we identified two novel TRIM50 partners, HDAC6 and p62, both involved in the clearance of polyubiquitinated and misfolded protein aggregates [2], [3], [4], [24]. The composition of the aggresome was partially solved by mass spectrometry [25], [26]. Song and colleagues showed that the higher proportion of aggresome-enriched proteins is related to molecular chaperones and ubiquitin-proteasome system components, involved in the elimination of misfolded and/or ubiquitinated proteins from cells [27]. Notably, a number of TRIM50 interactors that we have isolated in our proteomics approach, have been identified in a recent screening of proteins associated with MG132-induced aggresome in SH-SY5Y cells [26]. Among them are proteins known to interact with misfolded proteins and play a role in protein aggregation [28] including p62, chaperone proteins like Serpin H1, HSP90B1, PPIB, and 14-3-3 (eta and zeta) (Table S2). Moreover a number of the TRIM50-bound proteins were found ubiquitinated in previous studies [29], [30] or annotated in the Ubiprot database [31] (Table S2). Overall these data give additional evidences that TRIM50 bodies are aggresome precursors involved in the ubiquitination and aggregation process of misfolded proteins. We confirmed the interaction of TRIM50 with p62. p62 is a multifunctional adapter protein implicated in autophagy, cell signaling, receptor internalization, inflammation and protein turnover [22]. p62 is found in cytosolic protein aggregates that accumulate in various chronic, toxic, and degenerative diseases. It interacts with ubiquitinated proteins carrying them on the road to autophagy-mediated degradation [23], [32]. The TRIM50-p62 interacting region involves amino acids 302–370, a region that includes the LC3-Interacting Region (LIR) domain involved in the binding to LC3 (microtubule-associated protein 1A/1B light chain 3) [23] a modifier protein that plays a pivotal role in autophagosome biogenesis [33]. Interestingly we have some preliminary data showing that TRIM50 and LC3 colocalize in both normal and autophagy-induced conditions (Figure S4B and Fusco, unpublished results). Moreover using the NH4Cl autophagy inhibitor, we found that TRIM50 is partially degraded through the autophagy-lysosomal pathway (Figure 6). However how this degradation occurs remains yet unclear; one possibility is that TRIM50 could directly associate with LC3, or that TRIM50 could be addressed together with p62 to autophagy machinery for its degradation. In that way the observed colocalization between TRIM50 and LC3 is intriguing and deserves more investigations. These findings suggest also that p62 may serve as a scaffold protein, via the interaction with TRIM50, whereby chains of polyubiquitin are transferred to target substrates for degradation. Nevertheless it is tempting to speculate that TRIM50 might be involved in autophagy processes as well. Increasing evidences indicate that autophagy-related proteins are sequestrated into the aggresome as a selective mechanism to regulate their degradation [24]. Since aggresome formation mainly takes place in the insoluble fraction [34], [35] we assessed whether TRIM50 has a role in the accumulation of polyubiquitinted proteins. We observed that TRIM50 promotes the recruitment of polyubiquitinated proteins to aggresome and that the observed decrease of aggresome clearance was associated to the depletion of TRIM50 (Figure 5C), suggesting that these proteins are TRIM50 substrates. Overall the data reported in this study reveal a role for TRIM50 in aggresome formation and add further insights on its function by identifying and characterizing its first two protein partners. We speculate that, when the proteasome activity is impaired, TRIM50 ensures the sequestration of its targets to the aggresome via the association with HDAC6 and their subsequent likely removal by p62-mediated autophagy. Further studies, particularly the identification of TRIM50 specific substrates, are needed to unequivocally assess the authenticity of this model. Accumulation of polyubiquitinated protein aggregates is a hallmark of several neurodegenerative disorders as well as of a number of other protein aggregation diseases affecting muscles, heart, liver and lung [36], [37]. p62 has been identified as a component of inclusion bodies in several human diseases, such as neurodegenerative diseases (e.g., Alzheimer’s disease, Parkinson’s disease, and amyotrophic lateral sclerosis) and in liver diseases (e.g., alcoholic hepatitis, hepatic steatosis, and hepatocellular carcinoma) [38]. It will hence be interesting to investigate whether TRIM50 is also a component of such bodies and it could even be responsible for targeting p62 to these sites.

Materials and Methods

Fusion Plasmids

The pcDNA3-EGFP and pCDNA3-HA wild-type and mutants TRIM50 were described in [15]. Human β2-tubulin ORF was cloned into a pcDNA3 vector with FLAG as tag using a PCR based method with appropriate oligonucleotides followed by in-frame insertion into the vector. DsRED -LC3 and pENTR-EGFP, GST tagged p62 and GST-p62 mutants were a kind gift from Prof. T. Johansen (Institute of Medical Biology, University of Tromso, Norway), pcDNA3-Myc-p62 was a generous gift of Prof. Marie W. Wooten (Cellular and Molecular Biosciences Program, Auburn University, USA). pcDNA3-HA-HDAC6 mutants were a gift of Prof. Matthias (Friedrich Miescher Institute for Biomedical Research, Basel, Switzerland). The plasmids used in this study are listed in Table S1.

Cell Culture and Stable Cell Line Production

HEK293, HeLa cells, SH-SY5Y (all from ATCC, Manassas, USA), and MEF were maintained in DMEM with Glutamax medium supplemented with 10% fetal bovine serum and 1% antibiotics (Invitrogen, Carlsbad, CA). Hdac6 MEF (mouse embryo fibroblast) cells were kindly provided by Prof. Joo-Yong Lee (Duke University, Durham, USA) [39]. Fugene 6 (Roche) was used for transfection according to the manufacturers’ instructions. HEK293 were transfected with pcDNA3-FLAG-TRIM50 or empty vector and selected for 2 weeks with 1 mg/ml G418 (Invitrogen, Carlsbad, CA) selective agent. The expressing colonies were expanded and then used for protein extract preparations following standard procedures. HEK293 cell line was used since the low level expression of endogenous TRIM50 protein. Hereafter the stable cell lines will be referred to as FLAG-TRIM50#3 and FLAG#3, respectively.

Mouse Embryo Fibroblast Generation

To identify loss-of-function mutation in Trim50, we screened the sequence of the first exon of this gene in the sperm DNA archives of F1 male progeny of ENU-treated (ethylnitrosourea) males and untreated females established by INGENIUM (http://www.ingenium-ag.com). We identified two missense (V55M and V60G) and one nonsense mutation. The latter mutation creates a premature stop codon by modifying TGC into a TGA amber codon. This C52X mutation in the middle of the RING domain abrogates the E3-ligase activity of Trim50, as the next in frame methionine residue is situated in the coiled-coil domain after both the RING and the B-box type 2 of the Trim50-encoded protein. We recovered the nonsense mutant mouse from the frozen archive using in vitro fertilization. Due to the generation method, the first heterozygote mice (F1) have around twenty “background” mutations in addition to the wanted one. They were backcrossed with C3HeB/FeJ wild-type mice from Jackson laboratories for 12 generations to purge the strain of other mutations potentially induced by the ENU treatment. Mouse embryonic fibroblasts (MEFs) were prepared from E13.5 embryos as described in [40]. Cells were subsequently genotyped by Sanger sequencing to identify +/+, +/− and −/− lines. All procedures used with mice models and to generate the MEFs were approved by the CIG Institutional Animal Care and followed the National Institutes of Health Guidelines, ‘Using Animals in Intramural Research’. The work was approved by the ethics committee of the Veterinarian Cantonal Office (authorization Vaud-1958).

Immunofluorescence Microscopy

For immunofluorescence analyses, the cells transfected with EGFP-TRIM50 were fixed before their incubation with the primary and secondary antibodies of interest, mounted in mowiol and examined on a Zeiss LSM 510 META confocal microscope (Carl Zeiss, Jena, Germany). All confocal images were obtained using the necessary filter sets for GFP, Alexafluor 488 and 546, using a Zeiss Plan-Neofluor 63× oil immersion objective (NA 1.4), with the pinhole set to one Airey unit.

Live Cell Imaging and Fluorescent Recovery After Photobleaching (FRAP) Analyses

HeLa cells were transfected with EGFP-TRIM50 construct and observed at 37°C in 20mM HEPES buffered DMEM using a Zeiss LSM 510 META confocal microscope (Carl Zeiss, Jena, Germany). Temperature was controlled with a Nevtek air stream stage incubator (Burnsville, VA, USA) and images of live cells were acquired using sequential excitation at 488 nm and 543 nm. The tracking of moving objects and evaluation of their speed were performed using the Tracking macro of the ImageJ program. Selective photobleaching in the regions of interest within the cell was carried out on the Zeiss LSM510 using 100 iterations with a 488 nm laser line at full power.

Correlative Light Electron Microscopy (CLEM)

EGFP-TRIM50 transfected HeLa cells were grown on CELLocate coverslips with coordinated grid and then prepared for CLEM microscopy identification of TRIM50 structures according to Polishchuk et al. [41]. Briefly, after visualization of EGFP-TRIM50 positive bodies by time-lapse confocal microscopy, the cells were fixed, labeled with an antibody against EGFP using the gold-enhance protocol, embedded in Epon-812, and cut in serial sections. Then region containing TRIM50-positive bodies were analyzed in serial thin sections under a Philips Tecnai-12 electron microscope (Philips, Einhoven, The Netherlands). EM images were acquired from the region of interest using an Ultra View CCD digital camera (Soft Imaging Systems, Munich, Germany).

Statistical Analysis

All microscopy experiments were performed in triplicate. Approximately 40 cells were analyzed for each experimental condition. For the immunofluorescence experiments on Trim50-MEF cells, area, perimeter, and intensity of FK2-positive dots were measured using ImageJ program. The threshold was set to a level that excludes all the cytosolic background, thus allowing selective analysis of intense puncta representing the FK2-positive dots. Data were reported as median along with the upper and lower quartiles (Q1–Q3). Normal distribution assumption was checked by means of Q-Q plot, Shapiro-Wilks and Kolmogorov-Smirnov tests. The followed parameters were log transformed before statistical analyses because of their skewed distribution. Comparisons between wild-type, heterozygous and knockout mice were assessed by means of specific contrasts defined into a hierarchical linear model (HLM), accounting for clustering due to multiple measures collected within cell. All p-values were adjusted for multiple comparison following Tukey-Kramer’s method. A p-value <0.05 was considered for statistical significance. All statistical analyses and graphs were performed using SAS Release 9.1 (SAS Institute, Cary, NC, USA) and R (version 2.10.1) software, respectively.

Protein Identification by Mass Spectrometry Analysis

TRIM50 complexes were isolated from HEK293 cells total extracts by immunoprecipitation. FLAG-TRIM50#3 and FLAG#3 cell lines were lysed in PBS, 0.5% NP-40, 1 mM PMSF, and COMPLETE protease inhibitors (Roche) for 45 min under gently mixed. Total protein extracts were pre-cleared with unspecific Mouse IgG Agarose Beads (Sigma) overnight in lysis buffer. The protein extracts were recovered by centrifugation (3000 rpm for 5 min) and then incubated overnight, under gently agitation, onto M2 anti-FLAG agarose-conjugated antibody beads (Sigma) previously blocked with no fat milk treatment. Unbound proteins were discarded and the beads were collected by centrifugation and extensively washed with lysis buffer supplemented with 150 mM NaCl to eliminate non-specific bound proteins. Elution of the desired protein complexes was performed by competition with FLAG peptide in elution buffer. The eluted proteins were precipitated in methanol/chloroform and then loaded onto a 10% SDS-PAGE. The gel was stained with colloidal Coomassie blue (Pierce). Protein bands were excised from the gel, reduced, alkylated and digested with trypsin as described elsewhere (Zito et al., 2007). Peptide mixtures extracted from the gel were analyzed by nano-chromatography tandem mass spectrometry (nanoLC–MS/MS) on a CHIP MS Ion Trap XCT Ultra equipped with a capillary 1100 HPLC system and a chip cube (Agilent Technologies, Palo Alto, CA). Peptide analysis was performed using data-dependent acquisition of one MS scan (mass range from 400 to 2000 m/z) followed by MS/MS scans of the three most abundant ions in each MS scan. Raw data from nanoLC–MS/MS analyses were employed to query a non-redundant protein database using in house MASCOT software (Matrix Science, Boston, USA).

Immunoprecipitation, GST Pull-down and Western Blot

Co-immunoprecipitation experiments were performed as previously described [42]. Complexes were analyzed by western blotting using indicated antibodies. Horseradish peroxidase conjugated anti-mouse and anti-rabbit antibodies (GE Healthcare) and the ECL chemiluminescence system (GE Healthcare) was used for detection. Where indicated the MG132 proteasome inhibitor (Calbiochem, USA) was added. GST-p62 (231–385) and GST-p62 (232–370) fusion proteins were purified using glutathione-Sepharose 4B beads (GE Healthcare) according to the manufacturer’s instructions. For the GST pulldown assay, 3 µg of GST-recombinant proteins were mixed with 40 µg of total FLAG-TRIM50#3 cell lysate and incubated at 4°C for 2 h with rotation, and then incubated with FLAG antibody for 4 h. The binding fraction was washed four times and then loaded into a SDS 10% PAGE gel, and immunoblotted with anti-GST antibody (Santa Cruz). Soluble and insoluble fractions were obtained using RIPA buffer as described elsewhere (Muqit et al., 2006). Protein band densities were determined using densitometer (Kodak). The amount of the protein was calculated by the initial amount of FLAG-protein level and normalized with GAPDH. Cells treated with DMSO were used as control. TRIM50 does not colocalize with known and induced cellular organelles. (A) HeLa cells were transiently transfected with EGFP-TRIM50, fixed and stained for different cytoplasmic markers. The panel shows the merge of EGFP-TRIM50 (green) with single marker (red): Golgi markers (a,b,c,d,i), early endosomes (e), the coat complex of endoplasmic reticulum associated vesicles (f,g,h), lysosomes (j), cytoskeletal structures (k), and peroxisomes (l). (B) HeLa cells were transiently transfected with EGFP-TRIM50. After 24h the cells were cultured in presence of arsenite (0.5 mM for 30 min.) before processed and immunostained with anti-Eif3 for stress granules (b,c), and anti-HuR for P-bodies (e,f). (TIF) Click here for additional data file. Movement of TRIM50 particles and determination of the movement rates. (A) HeLa cells transiently expressing EGFP-TRIM50 were imaged over 110 frames at 0.5 sec intervals. The individual frames were summed using ImageJ. The tracks of three single particles are shown (blue, particle a; green, particle b; red, particle c). The asterisks indicate starting point of each particle. (B) Velocities of particles a–c were measured throughout the time that they were observed during the frames by using manual tracking plugin of ImageJ program. The vertical Y-axis shows the velocity of particles in each frame (micron/sec); the horizontal X-axis shows the relative time during the image sequence in which the particle was observed. (C) Recovery of the signal was measured throughout the time observed during 221 frames sequence using manual tracking of ImageJ program. (D) HeLa cells were transfected with EGFP-TRIM50, incubated for 30 min with TRITC-dextran, and imaged using confocal fluorescence microscopy. EM immunogold-labeled of a section corresponding to the area indicated by the box in figure D. (TIF) Click here for additional data file. TRIM50 interacts with beta tubulin. (A) Endogenous TRIM50 colocalizes with polyubiquitinated proteins. SH-SY5Y cells were stained with anti-TRIM50 antibody and with FK2 antibody. Where indicated, the cells were treated with 25 µM MG132 for 6 h. (B) HeLa cells expressing EGFP-TRIM50 were stained with an anti-HDAC6 antibody. The cells were treated with 25 µM MG132 for 6 h (d–f). (C) The interaction between TRIM50 and beta tubulin was assayed in HEK293 cells transiently expressing FLAG-Tubb2b and EGFP-TRIM50. The cell lysates were immunoprecipitated with anti-FLAG and immunoblotted with anti-GFP antibody. (TIF) Click here for additional data file. (A) TRIM50 E3-ubiquitin ligase activity is not required for aggresome localization. MEF Trim50−/− cell line was transfected with EGFP-Trim50ΔRING, treated with 25 µM MG132 for 6 h and stained with HDAC6 antibody (a–f). (B) TRIM50 colocalizes with LC3. HeLa cells were transiently co-transfected with HA-TRIM50 and DsRed-LC3 and stained with anti-HA antibody. After 24h the cells were incubated with EBSS medium for 2 h (d–f). (TIF) Click here for additional data file. TRIM50 increases the insolubility of p62 and HDAC6 into the aggresome. (A–B–C) TRIM50 promotes the sequestration of p62 and HDAC6 in aggresome. Lysates from FLAG-TRIM50#3 and FLAG#3 cell lines, treated with vehicle (–) or with MG132 (+) were separated in detergent-soluble and detergent insoluble fractions and immunoblotting with anti-FLAG and anti-p62 antibodies. An example for p62 protein is depicted (A). The asterisk shows the relative band of endogenous p62 of previous immunoblotting. The relative level of soluble and insoluble fractions was measured by quantification of the intensity of p62 (B) and HDAC6 (C) bands of three indipendent experiments. (TIF) Click here for additional data file. EGFP-TRIM50 bodies movement. Movies show a 110 frames sequence captured at 0.5 second intervals. (MOV) Click here for additional data file. FRAP analysis of TRIM50 cytoplasmic bodies. Movies show a 224 frames sequence captured at 0.5 second intervals. (MOV) Click here for additional data file. Plasmids used in this study. (DOC) Click here for additional data file. TRIM50-associated proteins found ubiquitinated and/or present within induced Aggresome. (DOC) Click here for additional data file.
  42 in total

Review 1.  Selective degradation of p62 by autophagy.

Authors:  Yoshinobu Ichimura; Masaaki Komatsu
Journal:  Semin Immunopathol       Date:  2010-09-03       Impact factor: 9.623

2.  HDAC6 and microtubules are required for autophagic degradation of aggregated huntingtin.

Authors:  Atsushi Iwata; Brigit E Riley; Jennifer A Johnston; Ron R Kopito
Journal:  J Biol Chem       Date:  2005-09-28       Impact factor: 5.157

3.  Retrovirus restriction by TRIM5alpha variants from Old World and New World primates.

Authors:  Byeongwoon Song; Hassan Javanbakht; Michel Perron; Do Hyun Park; Matthew Stremlau; Joseph Sodroski
Journal:  J Virol       Date:  2005-04       Impact factor: 5.103

Review 4.  Sequestosome 1/p62--more than just a scaffold.

Authors:  M Lamar Seibenhener; Thangiah Geetha; Marie W Wooten
Journal:  FEBS Lett       Date:  2006-12-19       Impact factor: 4.124

5.  p62 accumulates and enhances aggregate formation in model systems of familial amyotrophic lateral sclerosis.

Authors:  Jozsef Gal; Anna-Lena Ström; Renee Kilty; Fujian Zhang; Haining Zhu
Journal:  J Biol Chem       Date:  2007-02-12       Impact factor: 5.157

6.  Identification of additional transcripts in the Williams-Beuren syndrome critical region.

Authors:  Giuseppe Merla; Catherine Ucla; Michel Guipponi; Alexandre Reymond
Journal:  Hum Genet       Date:  2002-03-28       Impact factor: 4.132

Review 7.  Parkin-mediated ubiquitin signalling in aggresome formation and autophagy.

Authors:  Lih-Shen Chin; James A Olzmann; Lian Li
Journal:  Biochem Soc Trans       Date:  2010-02       Impact factor: 5.407

8.  The heavy metal cadmium induces valosin-containing protein (VCP)-mediated aggresome formation.

Authors:  Changcheng Song; Zhen Xiao; Kunio Nagashima; Chou-Chi H Li; Stephen J Lockett; Ren-Ming Dai; Edward H Cho; Thomas P Conrads; Timothy D Veenstra; Nancy H Colburn; Qing Wang; Ji Ming Wang
Journal:  Toxicol Appl Pharmacol       Date:  2008-01-08       Impact factor: 4.219

Review 9.  Autophagy in the pathogenesis of disease.

Authors:  Beth Levine; Guido Kroemer
Journal:  Cell       Date:  2008-01-11       Impact factor: 41.582

10.  Correlative light-electron microscopy reveals the tubular-saccular ultrastructure of carriers operating between Golgi apparatus and plasma membrane.

Authors:  R S Polishchuk; E V Polishchuk; P Marra; S Alberti; R Buccione; A Luini; A A Mironov
Journal:  J Cell Biol       Date:  2000-01-10       Impact factor: 10.539

View more
  29 in total

Review 1.  Regulation of autophagy by protein post-translational modification.

Authors:  Willayat Yousuf Wani; Michaël Boyer-Guittaut; Matthew Dodson; John Chatham; Victor Darley-Usmar; Jianhua Zhang
Journal:  Lab Invest       Date:  2014-11-03       Impact factor: 5.662

Review 2.  Precision autophagy directed by receptor regulators - emerging examples within the TRIM family.

Authors:  Tomonori Kimura; Michael Mandell; Vojo Deretic
Journal:  J Cell Sci       Date:  2016-02-15       Impact factor: 5.285

3.  TRIM proteins regulate autophagy and can target autophagic substrates by direct recognition.

Authors:  Michael A Mandell; Ashish Jain; John Arko-Mensah; Santosh Chauhan; Tomonori Kimura; Christina Dinkins; Guido Silvestri; Jan Münch; Frank Kirchhoff; Anne Simonsen; Yongjie Wei; Beth Levine; Terje Johansen; Vojo Deretic
Journal:  Dev Cell       Date:  2014-08-07       Impact factor: 12.270

4.  TRIM32, but not its muscular dystrophy-associated mutant, positively regulates and is targeted to autophagic degradation by p62/SQSTM1.

Authors:  Katrine Stange Overå; Juncal Garcia-Garcia; Zambarlal Bhujabal; Ashish Jain; Aud Øvervatn; Kenneth Bowitz Larsen; Vojo Deretic; Terje Johansen; Trond Lamark; Eva Sjøttem
Journal:  J Cell Sci       Date:  2019-12-02       Impact factor: 5.285

Review 5.  HDAC6: A unique HDAC family member as a cancer target.

Authors:  Sumeet Kaur; Prerna Rajoria; Madhu Chopra
Journal:  Cell Oncol (Dordr)       Date:  2022-08-29       Impact factor: 7.051

6.  Multilevel regulation of autophagosome content by ethanol oxidation in HepG2 cells.

Authors:  Paul G Thomes; Rebecca A Ehlers; Casey S Trambly; Dahn L Clemens; Howard S Fox; Dean J Tuma; Terrence M Donohue
Journal:  Autophagy       Date:  2012-10-22       Impact factor: 16.016

7.  Role of Cigarette Smoke-Induced Aggresome Formation in Chronic Obstructive Pulmonary Disease-Emphysema Pathogenesis.

Authors:  Ian Tran; Changhoon Ji; Inzer Ni; Taehong Min; Danni Tang; Neeraj Vij
Journal:  Am J Respir Cell Mol Biol       Date:  2015-08       Impact factor: 6.914

8.  The p97-UBXN1 complex regulates aggresome formation.

Authors:  Sirisha Mukkavalli; Jacob Aaron Klickstein; Betty Ortiz; Peter Juo; Malavika Raman
Journal:  J Cell Sci       Date:  2021-04-15       Impact factor: 5.285

9.  Guidelines for the use and interpretation of assays for monitoring autophagy (3rd edition).

Authors:  Daniel J Klionsky; Kotb Abdelmohsen; Akihisa Abe; Md Joynal Abedin; Hagai Abeliovich; Abraham Acevedo Arozena; Hiroaki Adachi; Christopher M Adams; Peter D Adams; Khosrow Adeli; Peter J Adhihetty; Sharon G Adler; Galila Agam; Rajesh Agarwal; Manish K Aghi; Maria Agnello; Patrizia Agostinis; Patricia V Aguilar; Julio Aguirre-Ghiso; Edoardo M Airoldi; Slimane Ait-Si-Ali; Takahiko Akematsu; Emmanuel T Akporiaye; Mohamed Al-Rubeai; Guillermo M Albaiceta; Chris Albanese; Diego Albani; Matthew L Albert; Jesus Aldudo; Hana Algül; Mehrdad Alirezaei; Iraide Alloza; Alexandru Almasan; Maylin Almonte-Beceril; Emad S Alnemri; Covadonga Alonso; Nihal Altan-Bonnet; Dario C Altieri; Silvia Alvarez; Lydia Alvarez-Erviti; Sandro Alves; Giuseppina Amadoro; Atsuo Amano; Consuelo Amantini; Santiago Ambrosio; Ivano Amelio; Amal O Amer; Mohamed Amessou; Angelika Amon; Zhenyi An; Frank A Anania; Stig U Andersen; Usha P Andley; Catherine K Andreadi; Nathalie Andrieu-Abadie; Alberto Anel; David K Ann; Shailendra Anoopkumar-Dukie; Manuela Antonioli; Hiroshi Aoki; Nadezda Apostolova; Saveria Aquila; Katia Aquilano; Koichi Araki; Eli Arama; Agustin Aranda; Jun Araya; Alexandre Arcaro; Esperanza Arias; Hirokazu Arimoto; Aileen R Ariosa; Jane L Armstrong; Thierry Arnould; Ivica Arsov; Katsuhiko Asanuma; Valerie Askanas; Eric Asselin; Ryuichiro Atarashi; Sally S Atherton; Julie D Atkin; Laura D Attardi; Patrick Auberger; Georg Auburger; Laure Aurelian; Riccardo Autelli; Laura Avagliano; Maria Laura Avantaggiati; Limor Avrahami; Suresh Awale; Neelam Azad; Tiziana Bachetti; Jonathan M Backer; Dong-Hun Bae; Jae-Sung Bae; Ok-Nam Bae; Soo Han Bae; Eric H Baehrecke; Seung-Hoon Baek; Stephen Baghdiguian; Agnieszka Bagniewska-Zadworna; Hua Bai; Jie Bai; Xue-Yuan Bai; Yannick Bailly; Kithiganahalli Narayanaswamy Balaji; Walter Balduini; Andrea Ballabio; Rena Balzan; Rajkumar Banerjee; Gábor Bánhegyi; Haijun Bao; Benoit Barbeau; Maria D Barrachina; Esther Barreiro; Bonnie Bartel; Alberto Bartolomé; Diane C Bassham; Maria Teresa Bassi; Robert C Bast; Alakananda Basu; Maria Teresa Batista; Henri Batoko; Maurizio Battino; Kyle Bauckman; Bradley L Baumgarner; K Ulrich Bayer; Rupert Beale; Jean-François Beaulieu; George R Beck; Christoph Becker; J David Beckham; Pierre-André Bédard; Patrick J Bednarski; Thomas J Begley; Christian Behl; Christian Behrends; Georg Mn Behrens; Kevin E Behrns; Eloy Bejarano; Amine Belaid; Francesca Belleudi; Giovanni Bénard; Guy Berchem; Daniele Bergamaschi; Matteo Bergami; Ben Berkhout; Laura Berliocchi; Amélie Bernard; Monique Bernard; Francesca Bernassola; Anne Bertolotti; Amanda S Bess; Sébastien Besteiro; Saverio Bettuzzi; Savita Bhalla; Shalmoli Bhattacharyya; Sujit K Bhutia; Caroline Biagosch; Michele Wolfe Bianchi; Martine Biard-Piechaczyk; Viktor Billes; Claudia Bincoletto; Baris Bingol; Sara W Bird; Marc Bitoun; Ivana Bjedov; Craig Blackstone; Lionel Blanc; Guillermo A Blanco; Heidi Kiil Blomhoff; Emilio Boada-Romero; Stefan Böckler; Marianne Boes; Kathleen Boesze-Battaglia; Lawrence H Boise; Alessandra Bolino; Andrea Boman; Paolo Bonaldo; Matteo Bordi; Jürgen Bosch; Luis M Botana; Joelle Botti; German Bou; Marina Bouché; Marion Bouchecareilh; Marie-Josée Boucher; Michael E Boulton; Sebastien G Bouret; Patricia Boya; Michaël Boyer-Guittaut; Peter V Bozhkov; Nathan Brady; Vania Mm Braga; Claudio Brancolini; Gerhard H Braus; José M Bravo-San Pedro; Lisa A Brennan; Emery H Bresnick; Patrick Brest; Dave Bridges; Marie-Agnès Bringer; Marisa Brini; Glauber C Brito; Bertha Brodin; Paul S Brookes; Eric J Brown; Karen Brown; Hal E Broxmeyer; Alain Bruhat; Patricia Chakur Brum; John H Brumell; Nicola Brunetti-Pierri; Robert J Bryson-Richardson; Shilpa Buch; Alastair M Buchan; Hikmet Budak; Dmitry V Bulavin; Scott J Bultman; Geert Bultynck; Vladimir Bumbasirevic; Yan Burelle; Robert E Burke; Margit Burmeister; Peter Bütikofer; Laura Caberlotto; Ken Cadwell; Monika Cahova; Dongsheng Cai; Jingjing Cai; Qian Cai; Sara Calatayud; Nadine Camougrand; Michelangelo Campanella; Grant R Campbell; Matthew Campbell; Silvia Campello; Robin Candau; Isabella Caniggia; Lavinia Cantoni; Lizhi Cao; Allan B Caplan; Michele Caraglia; Claudio Cardinali; Sandra Morais Cardoso; Jennifer S Carew; Laura A Carleton; Cathleen R Carlin; Silvia Carloni; Sven R Carlsson; Didac Carmona-Gutierrez; Leticia Am Carneiro; Oliana Carnevali; Serena Carra; Alice Carrier; Bernadette Carroll; Caty Casas; Josefina Casas; Giuliana Cassinelli; Perrine Castets; Susana Castro-Obregon; Gabriella Cavallini; Isabella Ceccherini; Francesco Cecconi; Arthur I Cederbaum; Valentín Ceña; Simone Cenci; Claudia Cerella; Davide Cervia; Silvia Cetrullo; Hassan Chaachouay; Han-Jung Chae; Andrei S Chagin; Chee-Yin Chai; Gopal Chakrabarti; Georgios Chamilos; Edmond Yw Chan; Matthew Tv Chan; Dhyan Chandra; Pallavi Chandra; Chih-Peng Chang; Raymond Chuen-Chung Chang; Ta Yuan Chang; John C Chatham; Saurabh Chatterjee; Santosh Chauhan; Yongsheng Che; Michael E Cheetham; Rajkumar Cheluvappa; Chun-Jung Chen; Gang Chen; Guang-Chao Chen; Guoqiang Chen; Hongzhuan Chen; Jeff W Chen; Jian-Kang Chen; Min Chen; Mingzhou Chen; Peiwen Chen; Qi Chen; Quan Chen; Shang-Der Chen; Si Chen; Steve S-L Chen; Wei Chen; Wei-Jung Chen; Wen Qiang Chen; Wenli Chen; Xiangmei Chen; Yau-Hung Chen; Ye-Guang Chen; Yin Chen; Yingyu Chen; Yongshun Chen; Yu-Jen Chen; Yue-Qin Chen; Yujie Chen; Zhen Chen; Zhong Chen; Alan Cheng; Christopher Hk Cheng; Hua Cheng; Heesun Cheong; Sara Cherry; Jason Chesney; Chun Hei Antonio Cheung; Eric Chevet; Hsiang Cheng Chi; Sung-Gil Chi; Fulvio Chiacchiera; Hui-Ling Chiang; Roberto Chiarelli; Mario Chiariello; Marcello Chieppa; Lih-Shen Chin; Mario Chiong; Gigi Nc Chiu; Dong-Hyung Cho; Ssang-Goo Cho; William C Cho; Yong-Yeon Cho; Young-Seok Cho; Augustine Mk Choi; Eui-Ju Choi; Eun-Kyoung Choi; Jayoung Choi; Mary E Choi; Seung-Il Choi; Tsui-Fen Chou; Salem Chouaib; Divaker Choubey; Vinay Choubey; Kuan-Chih Chow; Kamal Chowdhury; Charleen T Chu; Tsung-Hsien Chuang; Taehoon Chun; Hyewon Chung; Taijoon Chung; Yuen-Li Chung; Yong-Joon Chwae; Valentina Cianfanelli; Roberto Ciarcia; Iwona A Ciechomska; Maria Rosa Ciriolo; Mara Cirone; Sofie Claerhout; Michael J Clague; Joan Clària; Peter Gh Clarke; Robert Clarke; Emilio Clementi; Cédric Cleyrat; Miriam Cnop; Eliana M Coccia; Tiziana Cocco; Patrice Codogno; Jörn Coers; Ezra Ew Cohen; David Colecchia; Luisa Coletto; Núria S Coll; Emma Colucci-Guyon; Sergio Comincini; Maria Condello; Katherine L Cook; Graham H Coombs; Cynthia D Cooper; J Mark Cooper; Isabelle Coppens; Maria Tiziana Corasaniti; Marco Corazzari; Ramon Corbalan; Elisabeth Corcelle-Termeau; Mario D Cordero; Cristina Corral-Ramos; Olga Corti; Andrea Cossarizza; Paola Costelli; Safia Costes; Susan L Cotman; Ana Coto-Montes; Sandra Cottet; Eduardo Couve; Lori R Covey; L Ashley Cowart; Jeffery S Cox; Fraser P Coxon; Carolyn B Coyne; Mark S Cragg; Rolf J Craven; Tiziana Crepaldi; Jose L Crespo; Alfredo Criollo; Valeria Crippa; Maria Teresa Cruz; Ana Maria Cuervo; Jose M Cuezva; Taixing Cui; Pedro R Cutillas; Mark J Czaja; Maria F Czyzyk-Krzeska; Ruben K Dagda; Uta Dahmen; Chunsun Dai; Wenjie Dai; Yun Dai; Kevin N Dalby; Luisa Dalla Valle; Guillaume Dalmasso; Marcello D'Amelio; Markus Damme; Arlette Darfeuille-Michaud; Catherine Dargemont; Victor M Darley-Usmar; Srinivasan Dasarathy; Biplab Dasgupta; Srikanta Dash; Crispin R Dass; Hazel Marie Davey; Lester M Davids; David Dávila; Roger J Davis; Ted M Dawson; Valina L Dawson; Paula Daza; Jackie de Belleroche; Paul de Figueiredo; Regina Celia Bressan Queiroz de Figueiredo; José de la Fuente; Luisa De Martino; Antonella De Matteis; Guido Ry De Meyer; Angelo De Milito; Mauro De Santi; Wanderley de Souza; Vincenzo De Tata; Daniela De Zio; Jayanta Debnath; Reinhard Dechant; Jean-Paul Decuypere; Shane Deegan; Benjamin Dehay; Barbara Del Bello; Dominic P Del Re; Régis Delage-Mourroux; Lea Md Delbridge; Louise Deldicque; Elizabeth Delorme-Axford; Yizhen Deng; Joern Dengjel; Melanie Denizot; Paul Dent; Channing J Der; Vojo Deretic; Benoît Derrien; Eric Deutsch; Timothy P Devarenne; Rodney J Devenish; Sabrina Di Bartolomeo; Nicola Di Daniele; Fabio Di Domenico; Alessia Di Nardo; Simone Di Paola; Antonio Di Pietro; Livia Di Renzo; Aaron DiAntonio; Guillermo Díaz-Araya; Ines Díaz-Laviada; Maria T Diaz-Meco; Javier Diaz-Nido; Chad A Dickey; Robert C Dickson; Marc Diederich; Paul Digard; Ivan Dikic; Savithrama P Dinesh-Kumar; Chan Ding; Wen-Xing Ding; Zufeng Ding; Luciana Dini; Jörg Hw Distler; Abhinav Diwan; Mojgan Djavaheri-Mergny; Kostyantyn Dmytruk; Renwick Cj Dobson; Volker Doetsch; Karol Dokladny; Svetlana Dokudovskaya; Massimo Donadelli; X Charlie Dong; Xiaonan Dong; Zheng Dong; Terrence M Donohue; Kelly S Doran; Gabriella D'Orazi; Gerald W Dorn; Victor Dosenko; Sami Dridi; Liat Drucker; Jie Du; Li-Lin Du; Lihuan Du; André du Toit; Priyamvada Dua; Lei Duan; Pu Duann; Vikash Kumar Dubey; Michael R Duchen; Michel A Duchosal; Helene Duez; Isabelle Dugail; Verónica I Dumit; Mara C Duncan; Elaine A Dunlop; William A Dunn; Nicolas Dupont; Luc Dupuis; Raúl V Durán; Thomas M Durcan; Stéphane Duvezin-Caubet; Umamaheswar Duvvuri; Vinay Eapen; Darius Ebrahimi-Fakhari; Arnaud Echard; Leopold Eckhart; Charles L Edelstein; Aimee L Edinger; Ludwig Eichinger; Tobias Eisenberg; Avital Eisenberg-Lerner; N Tony Eissa; Wafik S El-Deiry; Victoria El-Khoury; Zvulun Elazar; Hagit Eldar-Finkelman; Chris Jh Elliott; Enzo Emanuele; Urban Emmenegger; Nikolai Engedal; Anna-Mart Engelbrecht; Simone Engelender; Jorrit M Enserink; Ralf Erdmann; Jekaterina Erenpreisa; Rajaraman Eri; Jason L Eriksen; Andreja Erman; Ricardo Escalante; Eeva-Liisa Eskelinen; Lucile Espert; Lorena Esteban-Martínez; Thomas J Evans; Mario Fabri; Gemma Fabrias; Cinzia Fabrizi; Antonio Facchiano; Nils J Færgeman; Alberto Faggioni; W Douglas Fairlie; Chunhai Fan; Daping Fan; Jie Fan; Shengyun Fang; Manolis Fanto; Alessandro Fanzani; Thomas Farkas; Mathias Faure; Francois B Favier; Howard Fearnhead; Massimo Federici; Erkang Fei; Tania C Felizardo; Hua Feng; Yibin Feng; Yuchen Feng; Thomas A Ferguson; Álvaro F Fernández; Maite G Fernandez-Barrena; Jose C Fernandez-Checa; Arsenio Fernández-López; Martin E Fernandez-Zapico; Olivier Feron; Elisabetta Ferraro; Carmen Veríssima Ferreira-Halder; Laszlo Fesus; Ralph Feuer; Fabienne C Fiesel; Eduardo C Filippi-Chiela; Giuseppe Filomeni; Gian Maria Fimia; John H Fingert; Steven Finkbeiner; Toren Finkel; Filomena Fiorito; Paul B Fisher; Marc Flajolet; Flavio Flamigni; Oliver Florey; Salvatore Florio; R Andres Floto; Marco Folini; Carlo Follo; Edward A Fon; Francesco Fornai; Franco Fortunato; Alessandro Fraldi; Rodrigo Franco; Arnaud Francois; Aurélie François; Lisa B Frankel; Iain Dc Fraser; Norbert Frey; Damien G Freyssenet; Christian Frezza; Scott L Friedman; Daniel E Frigo; Dongxu Fu; José M Fuentes; Juan Fueyo; Yoshio Fujitani; Yuuki Fujiwara; Mikihiro Fujiya; Mitsunori Fukuda; Simone Fulda; Carmela Fusco; Bozena Gabryel; Matthias Gaestel; Philippe Gailly; Malgorzata Gajewska; Sehamuddin Galadari; Gad Galili; Inmaculada Galindo; Maria F Galindo; Giovanna Galliciotti; Lorenzo Galluzzi; Luca Galluzzi; Vincent Galy; Noor Gammoh; Sam Gandy; Anand K Ganesan; Swamynathan Ganesan; Ian G Ganley; Monique Gannagé; Fen-Biao Gao; Feng Gao; Jian-Xin Gao; Lorena García Nannig; Eleonora García Véscovi; Marina Garcia-Macía; Carmen Garcia-Ruiz; Abhishek D Garg; Pramod Kumar Garg; Ricardo Gargini; Nils Christian Gassen; Damián Gatica; Evelina Gatti; Julie Gavard; Evripidis Gavathiotis; Liang Ge; Pengfei Ge; Shengfang Ge; Po-Wu Gean; Vania Gelmetti; Armando A Genazzani; Jiefei Geng; Pascal Genschik; Lisa Gerner; Jason E Gestwicki; David A Gewirtz; Saeid Ghavami; Eric Ghigo; Debabrata Ghosh; Anna Maria Giammarioli; Francesca Giampieri; Claudia Giampietri; Alexandra Giatromanolaki; Derrick J Gibbings; Lara Gibellini; Spencer B Gibson; Vanessa Ginet; Antonio Giordano; Flaviano Giorgini; Elisa Giovannetti; Stephen E Girardin; Suzana Gispert; Sandy Giuliano; Candece L Gladson; Alvaro Glavic; Martin Gleave; Nelly Godefroy; Robert M Gogal; Kuppan Gokulan; Gustavo H Goldman; Delia Goletti; Michael S Goligorsky; Aldrin V Gomes; Ligia C Gomes; Hernando Gomez; Candelaria Gomez-Manzano; Rubén Gómez-Sánchez; Dawit Ap Gonçalves; Ebru Goncu; Qingqiu Gong; Céline Gongora; Carlos B Gonzalez; Pedro Gonzalez-Alegre; Pilar Gonzalez-Cabo; Rosa Ana González-Polo; Ing Swie Goping; Carlos Gorbea; Nikolai V Gorbunov; Daphne R Goring; Adrienne M Gorman; Sharon M Gorski; Sandro Goruppi; Shino Goto-Yamada; Cecilia Gotor; Roberta A Gottlieb; Illana Gozes; Devrim Gozuacik; Yacine Graba; Martin Graef; Giovanna E Granato; Gary Dean Grant; Steven Grant; Giovanni Luca Gravina; Douglas R Green; Alexander Greenhough; Michael T Greenwood; Benedetto Grimaldi; Frédéric Gros; Charles Grose; Jean-Francois Groulx; Florian Gruber; Paolo Grumati; Tilman Grune; Jun-Lin Guan; Kun-Liang Guan; Barbara Guerra; Carlos Guillen; Kailash Gulshan; Jan Gunst; Chuanyong Guo; Lei Guo; Ming Guo; Wenjie Guo; Xu-Guang Guo; Andrea A Gust; Åsa B Gustafsson; Elaine Gutierrez; Maximiliano G Gutierrez; Ho-Shin Gwak; Albert Haas; James E Haber; Shinji Hadano; Monica Hagedorn; David R Hahn; Andrew J Halayko; Anne Hamacher-Brady; Kozo Hamada; Ahmed Hamai; Andrea Hamann; Maho Hamasaki; Isabelle Hamer; Qutayba Hamid; Ester M Hammond; Feng Han; Weidong Han; James T Handa; John A Hanover; Malene Hansen; Masaru Harada; Ljubica Harhaji-Trajkovic; J Wade Harper; Abdel Halim Harrath; Adrian L Harris; James Harris; Udo Hasler; Peter Hasselblatt; Kazuhisa Hasui; Robert G Hawley; Teresa S Hawley; Congcong He; Cynthia Y He; Fengtian He; Gu He; Rong-Rong He; Xian-Hui He; You-Wen He; Yu-Ying He; Joan K Heath; Marie-Josée Hébert; Robert A Heinzen; Gudmundur Vignir Helgason; Michael Hensel; Elizabeth P Henske; Chengtao Her; Paul K Herman; Agustín Hernández; Carlos Hernandez; Sonia Hernández-Tiedra; Claudio Hetz; P Robin Hiesinger; Katsumi Higaki; Sabine Hilfiker; Bradford G Hill; Joseph A Hill; William D Hill; Keisuke Hino; Daniel Hofius; Paul Hofman; Günter U Höglinger; Jörg Höhfeld; Marina K Holz; Yonggeun Hong; David A Hood; Jeroen Jm Hoozemans; Thorsten Hoppe; Chin Hsu; Chin-Yuan Hsu; Li-Chung Hsu; Dong Hu; Guochang Hu; Hong-Ming Hu; Hongbo Hu; Ming Chang Hu; Yu-Chen Hu; Zhuo-Wei Hu; Fang Hua; Ya Hua; Canhua Huang; Huey-Lan Huang; Kuo-How Huang; Kuo-Yang Huang; Shile Huang; Shiqian Huang; Wei-Pang Huang; Yi-Ran Huang; Yong Huang; Yunfei Huang; Tobias B Huber; Patricia Huebbe; Won-Ki Huh; Juha J Hulmi; Gang Min Hur; James H Hurley; Zvenyslava Husak; Sabah Na Hussain; Salik Hussain; Jung Jin Hwang; Seungmin Hwang; Thomas Is Hwang; Atsuhiro Ichihara; Yuzuru Imai; Carol Imbriano; Megumi Inomata; Takeshi Into; Valentina Iovane; Juan L Iovanna; Renato V Iozzo; Nancy Y Ip; Javier E Irazoqui; Pablo Iribarren; Yoshitaka Isaka; Aleksandra J Isakovic; Harry Ischiropoulos; Jeffrey S Isenberg; Mohammad Ishaq; Hiroyuki Ishida; Isao Ishii; Jane E Ishmael; Ciro Isidoro; Ken-Ichi Isobe; Erika Isono; Shohreh Issazadeh-Navikas; Koji Itahana; Eisuke Itakura; Andrei I Ivanov; Anand Krishnan V Iyer; José M Izquierdo; Yotaro Izumi; Valentina Izzo; Marja Jäättelä; Nadia Jaber; Daniel John Jackson; William T Jackson; Tony George Jacob; Thomas S Jacques; Chinnaswamy Jagannath; Ashish Jain; Nihar Ranjan Jana; Byoung Kuk Jang; Alkesh Jani; Bassam Janji; Paulo Roberto Jannig; Patric J Jansson; Steve Jean; Marina Jendrach; Ju-Hong Jeon; Niels Jessen; Eui-Bae Jeung; Kailiang Jia; Lijun Jia; Hong Jiang; Hongchi Jiang; Liwen Jiang; Teng Jiang; Xiaoyan Jiang; Xuejun Jiang; Xuejun Jiang; Ying Jiang; Yongjun Jiang; Alberto Jiménez; Cheng Jin; Hongchuan Jin; Lei Jin; Meiyan Jin; Shengkan Jin; Umesh Kumar Jinwal; Eun-Kyeong Jo; Terje Johansen; Daniel E Johnson; Gail Vw Johnson; James D Johnson; Eric Jonasch; Chris Jones; Leo Ab Joosten; Joaquin Jordan; Anna-Maria Joseph; Bertrand Joseph; Annie M Joubert; Dianwen Ju; Jingfang Ju; Hsueh-Fen Juan; Katrin Juenemann; Gábor Juhász; Hye Seung Jung; Jae U Jung; Yong-Keun Jung; Heinz Jungbluth; Matthew J Justice; Barry Jutten; Nadeem O Kaakoush; Kai Kaarniranta; Allen Kaasik; Tomohiro Kabuta; Bertrand Kaeffer; Katarina Kågedal; Alon Kahana; Shingo Kajimura; Or Kakhlon; Manjula Kalia; Dhan V Kalvakolanu; Yoshiaki Kamada; Konstantinos Kambas; Vitaliy O Kaminskyy; Harm H Kampinga; Mustapha Kandouz; Chanhee Kang; Rui Kang; Tae-Cheon Kang; Tomotake Kanki; Thirumala-Devi Kanneganti; Haruo Kanno; Anumantha G Kanthasamy; Marc Kantorow; Maria Kaparakis-Liaskos; Orsolya Kapuy; Vassiliki Karantza; Md Razaul Karim; Parimal Karmakar; Arthur Kaser; Susmita Kaushik; Thomas Kawula; A Murat Kaynar; Po-Yuan Ke; Zun-Ji Ke; John H Kehrl; Kate E Keller; Jongsook Kim Kemper; Anne K Kenworthy; Oliver Kepp; Andreas Kern; Santosh Kesari; David Kessel; Robin Ketteler; Isis do Carmo Kettelhut; Bilon Khambu; Muzamil Majid Khan; Vinoth Km Khandelwal; Sangeeta Khare; Juliann G Kiang; Amy A Kiger; Akio Kihara; Arianna L Kim; Cheol Hyeon Kim; Deok Ryong Kim; Do-Hyung Kim; Eung Kweon Kim; Hye Young Kim; Hyung-Ryong Kim; Jae-Sung Kim; Jeong Hun Kim; Jin Cheon Kim; Jin Hyoung Kim; Kwang Woon Kim; Michael D Kim; Moon-Moo Kim; Peter K Kim; Seong Who Kim; Soo-Youl Kim; Yong-Sun Kim; Yonghyun Kim; Adi Kimchi; Alec C Kimmelman; Tomonori Kimura; Jason S King; Karla Kirkegaard; Vladimir Kirkin; Lorrie A Kirshenbaum; Shuji Kishi; Yasuo Kitajima; Katsuhiko Kitamoto; Yasushi Kitaoka; Kaio Kitazato; Rudolf A Kley; Walter T Klimecki; Michael Klinkenberg; Jochen Klucken; Helene Knævelsrud; Erwin Knecht; Laura Knuppertz; Jiunn-Liang Ko; Satoru Kobayashi; Jan C Koch; Christelle Koechlin-Ramonatxo; Ulrich Koenig; Young Ho Koh; Katja Köhler; Sepp D Kohlwein; Masato Koike; Masaaki Komatsu; Eiki Kominami; Dexin Kong; Hee Jeong Kong; Eumorphia G Konstantakou; Benjamin T Kopp; Tamas Korcsmaros; Laura Korhonen; Viktor I Korolchuk; Nadya V Koshkina; Yanjun Kou; Michael I Koukourakis; Constantinos Koumenis; Attila L Kovács; Tibor Kovács; Werner J Kovacs; Daisuke Koya; Claudine Kraft; Dimitri Krainc; Helmut Kramer; Tamara Kravic-Stevovic; Wilhelm Krek; Carole Kretz-Remy; Roswitha Krick; Malathi Krishnamurthy; Janos Kriston-Vizi; Guido Kroemer; Michael C Kruer; Rejko Kruger; Nicholas T Ktistakis; Kazuyuki Kuchitsu; Christian Kuhn; Addanki Pratap Kumar; Anuj Kumar; Ashok Kumar; Deepak Kumar; Dhiraj Kumar; Rakesh Kumar; Sharad Kumar; Mondira Kundu; Hsing-Jien Kung; Atsushi Kuno; Sheng-Han Kuo; Jeff Kuret; Tino Kurz; Terry Kwok; Taeg Kyu Kwon; Yong Tae Kwon; Irene Kyrmizi; Albert R La Spada; Frank Lafont; Tim Lahm; Aparna Lakkaraju; Truong Lam; Trond Lamark; Steve Lancel; Terry H Landowski; Darius J R Lane; Jon D Lane; Cinzia Lanzi; Pierre Lapaquette; Louis R Lapierre; Jocelyn Laporte; Johanna Laukkarinen; Gordon W Laurie; Sergio Lavandero; Lena Lavie; Matthew J LaVoie; Betty Yuen Kwan Law; Helen Ka-Wai Law; Kelsey B Law; Robert Layfield; Pedro A Lazo; Laurent Le Cam; Karine G Le Roch; Hervé Le Stunff; Vijittra Leardkamolkarn; Marc Lecuit; Byung-Hoon Lee; Che-Hsin Lee; Erinna F Lee; Gyun Min Lee; He-Jin Lee; Hsinyu Lee; Jae Keun Lee; Jongdae Lee; Ju-Hyun Lee; Jun Hee Lee; Michael Lee; Myung-Shik Lee; Patty J Lee; Sam W Lee; Seung-Jae Lee; Shiow-Ju Lee; Stella Y Lee; Sug Hyung Lee; Sung Sik Lee; Sung-Joon Lee; Sunhee Lee; Ying-Ray Lee; Yong J Lee; Young H Lee; Christiaan Leeuwenburgh; Sylvain Lefort; Renaud Legouis; Jinzhi Lei; Qun-Ying Lei; David A Leib; Gil Leibowitz; Istvan Lekli; Stéphane D Lemaire; John J Lemasters; Marius K Lemberg; Antoinette Lemoine; Shuilong Leng; Guido Lenz; Paola Lenzi; Lilach O Lerman; Daniele Lettieri Barbato; Julia I-Ju Leu; Hing Y Leung; Beth Levine; Patrick A Lewis; Frank Lezoualc'h; Chi Li; Faqiang Li; Feng-Jun Li; Jun Li; Ke Li; Lian Li; Min Li; Min Li; Qiang Li; Rui Li; Sheng Li; Wei Li; Wei Li; Xiaotao Li; Yumin Li; Jiqin Lian; Chengyu Liang; Qiangrong Liang; Yulin Liao; Joana Liberal; Pawel P Liberski; Pearl Lie; Andrew P Lieberman; Hyunjung Jade Lim; Kah-Leong Lim; Kyu Lim; Raquel T Lima; Chang-Shen Lin; Chiou-Feng Lin; Fang Lin; Fangming Lin; Fu-Cheng Lin; Kui Lin; Kwang-Huei Lin; Pei-Hui Lin; Tianwei Lin; Wan-Wan Lin; Yee-Shin Lin; Yong Lin; Rafael Linden; Dan Lindholm; Lisa M Lindqvist; Paul Lingor; Andreas Linkermann; Lance A Liotta; Marta M Lipinski; Vitor A Lira; Michael P Lisanti; Paloma B Liton; Bo Liu; Chong Liu; Chun-Feng Liu; Fei Liu; Hung-Jen Liu; Jianxun Liu; Jing-Jing Liu; Jing-Lan Liu; Ke Liu; Leyuan Liu; Liang Liu; Quentin Liu; Rong-Yu Liu; Shiming Liu; Shuwen Liu; Wei Liu; Xian-De Liu; Xiangguo Liu; Xiao-Hong Liu; Xinfeng Liu; Xu Liu; Xueqin Liu; Yang Liu; Yule Liu; Zexian Liu; Zhe Liu; Juan P Liuzzi; Gérard Lizard; Mila Ljujic; Irfan J Lodhi; Susan E Logue; Bal L Lokeshwar; Yun Chau Long; Sagar Lonial; Benjamin Loos; Carlos López-Otín; Cristina López-Vicario; Mar Lorente; Philip L Lorenzi; Péter Lõrincz; Marek Los; Michael T Lotze; Penny E Lovat; Binfeng Lu; Bo Lu; Jiahong Lu; Qing Lu; She-Min Lu; Shuyan Lu; Yingying Lu; Frédéric Luciano; Shirley Luckhart; John Milton Lucocq; Paula Ludovico; Aurelia Lugea; Nicholas W Lukacs; Julian J Lum; Anders H Lund; Honglin Luo; Jia Luo; Shouqing Luo; Claudio Luparello; Timothy Lyons; Jianjie Ma; Yi Ma; Yong Ma; Zhenyi Ma; Juliano Machado; Glaucia M Machado-Santelli; Fernando Macian; Gustavo C MacIntosh; Jeffrey P MacKeigan; Kay F Macleod; John D MacMicking; Lee Ann MacMillan-Crow; Frank Madeo; Muniswamy Madesh; Julio Madrigal-Matute; Akiko Maeda; Tatsuya Maeda; Gustavo Maegawa; Emilia Maellaro; Hannelore Maes; Marta Magariños; Kenneth Maiese; Tapas K Maiti; Luigi Maiuri; Maria Chiara Maiuri; Carl G Maki; Roland Malli; Walter Malorni; Alina Maloyan; Fathia Mami-Chouaib; Na Man; Joseph D Mancias; Eva-Maria Mandelkow; Michael A Mandell; Angelo A Manfredi; Serge N Manié; Claudia Manzoni; Kai Mao; Zixu Mao; Zong-Wan Mao; Philippe Marambaud; Anna Maria Marconi; Zvonimir Marelja; Gabriella Marfe; Marta Margeta; Eva Margittai; Muriel Mari; Francesca V Mariani; Concepcio Marin; Sara Marinelli; Guillermo Mariño; Ivanka Markovic; Rebecca Marquez; Alberto M Martelli; Sascha Martens; Katie R Martin; Seamus J Martin; Shaun Martin; Miguel A Martin-Acebes; Paloma Martín-Sanz; Camille Martinand-Mari; Wim Martinet; Jennifer Martinez; Nuria Martinez-Lopez; Ubaldo Martinez-Outschoorn; Moisés Martínez-Velázquez; Marta Martinez-Vicente; Waleska Kerllen Martins; Hirosato Mashima; James A Mastrianni; Giuseppe Matarese; Paola Matarrese; Roberto Mateo; Satoaki Matoba; Naomichi Matsumoto; Takehiko Matsushita; Akira Matsuura; Takeshi Matsuzawa; Mark P Mattson; Soledad Matus; Norma Maugeri; Caroline Mauvezin; Andreas Mayer; Dusica Maysinger; Guillermo D Mazzolini; Mary Kate McBrayer; Kimberly McCall; Craig McCormick; Gerald M McInerney; Skye C McIver; Sharon McKenna; John J McMahon; Iain A McNeish; Fatima Mechta-Grigoriou; Jan Paul Medema; Diego L Medina; Klara Megyeri; Maryam Mehrpour; Jawahar L Mehta; Yide Mei; Ute-Christiane Meier; Alfred J Meijer; Alicia Meléndez; Gerry Melino; Sonia Melino; Edesio Jose Tenorio de Melo; Maria A Mena; Marc D Meneghini; Javier A Menendez; Regina Menezes; Liesu Meng; Ling-Hua Meng; Songshu Meng; Rossella Menghini; A Sue Menko; Rubem Fs Menna-Barreto; Manoj B Menon; Marco A Meraz-Ríos; Giuseppe Merla; Luciano Merlini; Angelica M Merlot; Andreas Meryk; Stefania Meschini; Joel N Meyer; Man-Tian Mi; Chao-Yu Miao; Lucia Micale; Simon Michaeli; Carine Michiels; Anna Rita Migliaccio; Anastasia Susie Mihailidou; Dalibor Mijaljica; Katsuhiko Mikoshiba; Enrico Milan; Leonor Miller-Fleming; Gordon B Mills; Ian G Mills; Georgia Minakaki; Berge A Minassian; Xiu-Fen Ming; Farida Minibayeva; Elena A Minina; Justine D Mintern; Saverio Minucci; Antonio Miranda-Vizuete; Claire H Mitchell; Shigeki Miyamoto; Keisuke Miyazawa; Noboru Mizushima; Katarzyna Mnich; Baharia Mograbi; Simin Mohseni; Luis Ferreira Moita; Marco Molinari; Maurizio Molinari; Andreas Buch Møller; Bertrand Mollereau; Faustino Mollinedo; Marco Mongillo; Martha M Monick; Serena Montagnaro; Craig Montell; Darren J Moore; Michael N Moore; Rodrigo Mora-Rodriguez; Paula I Moreira; Etienne Morel; Maria Beatrice Morelli; Sandra Moreno; Michael J Morgan; Arnaud Moris; Yuji Moriyasu; Janna L Morrison; Lynda A Morrison; Eugenia Morselli; Jorge Moscat; Pope L Moseley; Serge Mostowy; Elisa Motori; Denis Mottet; Jeremy C Mottram; Charbel E-H Moussa; Vassiliki E Mpakou; Hasan Mukhtar; Jean M Mulcahy Levy; Sylviane Muller; Raquel Muñoz-Moreno; Cristina Muñoz-Pinedo; Christian Münz; Maureen E Murphy; James T Murray; Aditya Murthy; Indira U Mysorekar; Ivan R Nabi; Massimo Nabissi; Gustavo A Nader; Yukitoshi Nagahara; Yoshitaka Nagai; Kazuhiro Nagata; Anika Nagelkerke; Péter Nagy; Samisubbu R Naidu; Sreejayan Nair; Hiroyasu Nakano; Hitoshi Nakatogawa; Meera Nanjundan; Gennaro Napolitano; Naweed I Naqvi; Roberta Nardacci; Derek P Narendra; Masashi Narita; Anna Chiara Nascimbeni; Ramesh Natarajan; Luiz C Navegantes; Steffan T Nawrocki; Taras Y Nazarko; Volodymyr Y Nazarko; Thomas Neill; Luca M Neri; Mihai G Netea; Romana T Netea-Maier; Bruno M Neves; Paul A Ney; Ioannis P Nezis; Hang Tt Nguyen; Huu Phuc Nguyen; Anne-Sophie Nicot; Hilde Nilsen; Per Nilsson; Mikio Nishimura; Ichizo Nishino; Mireia Niso-Santano; Hua Niu; Ralph A Nixon; Vincent Co Njar; Takeshi Noda; Angelika A Noegel; Elsie Magdalena Nolte; Erik Norberg; Koenraad K Norga; Sakineh Kazemi Noureini; Shoji Notomi; Lucia Notterpek; Karin Nowikovsky; Nobuyuki Nukina; Thorsten Nürnberger; Valerie B O'Donnell; Tracey O'Donovan; Peter J O'Dwyer; Ina Oehme; Clara L Oeste; Michinaga Ogawa; Besim Ogretmen; Yuji Ogura; Young J Oh; Masaki Ohmuraya; Takayuki Ohshima; Rani Ojha; Koji Okamoto; Toshiro Okazaki; F Javier Oliver; Karin Ollinger; Stefan Olsson; Daniel P Orban; Paulina Ordonez; Idil Orhon; Laszlo Orosz; Eyleen J O'Rourke; Helena Orozco; Angel L Ortega; Elena Ortona; Laura D Osellame; Junko Oshima; Shigeru Oshima; Heinz D Osiewacz; Takanobu Otomo; Kinya Otsu; Jing-Hsiung James Ou; Tiago F Outeiro; Dong-Yun Ouyang; Hongjiao Ouyang; Michael Overholtzer; Michelle A Ozbun; P Hande Ozdinler; Bulent Ozpolat; Consiglia Pacelli; Paolo Paganetti; Guylène Page; Gilles Pages; Ugo Pagnini; Beata Pajak; Stephen C Pak; Karolina Pakos-Zebrucka; Nazzy Pakpour; Zdena Palková; Francesca Palladino; Kathrin Pallauf; Nicolas Pallet; Marta Palmieri; Søren R Paludan; Camilla Palumbo; Silvia Palumbo; Olatz Pampliega; Hongming Pan; Wei Pan; Theocharis Panaretakis; Aseem Pandey; Areti Pantazopoulou; Zuzana Papackova; Daniela L Papademetrio; Issidora Papassideri; Alessio Papini; Nirmala Parajuli; Julian Pardo; Vrajesh V Parekh; Giancarlo Parenti; Jong-In Park; Junsoo Park; Ohkmae K Park; Roy Parker; Rosanna Parlato; Jan B Parys; Katherine R Parzych; Jean-Max Pasquet; Benoit Pasquier; Kishore Bs Pasumarthi; Daniel Patschan; Cam Patterson; Sophie Pattingre; Scott Pattison; Arnim Pause; Hermann Pavenstädt; Flaminia Pavone; Zully Pedrozo; Fernando J Peña; Miguel A Peñalva; Mario Pende; Jianxin Peng; Fabio Penna; Josef M Penninger; Anna Pensalfini; Salvatore Pepe; Gustavo Js Pereira; Paulo C Pereira; Verónica Pérez-de la Cruz; María Esther Pérez-Pérez; Diego Pérez-Rodríguez; Dolores Pérez-Sala; Celine Perier; Andras Perl; David H Perlmutter; Ida Perrotta; Shazib Pervaiz; Maija Pesonen; Jeffrey E Pessin; Godefridus J Peters; Morten Petersen; Irina Petrache; Basil J Petrof; Goran Petrovski; James M Phang; Mauro Piacentini; Marina Pierdominici; Philippe Pierre; Valérie Pierrefite-Carle; Federico Pietrocola; Felipe X Pimentel-Muiños; Mario Pinar; Benjamin Pineda; Ronit Pinkas-Kramarski; Marcello Pinti; Paolo Pinton; Bilal Piperdi; James M Piret; Leonidas C Platanias; Harald W Platta; Edward D Plowey; Stefanie Pöggeler; Marc Poirot; Peter Polčic; Angelo Poletti; Audrey H Poon; Hana Popelka; Blagovesta Popova; Izabela Poprawa; Shibu M Poulose; Joanna Poulton; Scott K Powers; Ted Powers; Mercedes Pozuelo-Rubio; Krisna Prak; Reinhild Prange; Mark Prescott; Muriel Priault; Sharon Prince; Richard L Proia; Tassula Proikas-Cezanne; Holger Prokisch; Vasilis J Promponas; Karin Przyklenk; Rosa Puertollano; Subbiah Pugazhenthi; Luigi Puglielli; Aurora Pujol; Julien Puyal; Dohun Pyeon; Xin Qi; Wen-Bin Qian; Zheng-Hong Qin; Yu Qiu; Ziwei Qu; Joe Quadrilatero; Frederick Quinn; Nina Raben; Hannah Rabinowich; Flavia Radogna; Michael J Ragusa; Mohamed Rahmani; Komal Raina; Sasanka Ramanadham; Rajagopal Ramesh; Abdelhaq Rami; Sarron Randall-Demllo; Felix Randow; Hai Rao; V Ashutosh Rao; Blake B Rasmussen; Tobias M Rasse; Edward A Ratovitski; Pierre-Emmanuel Rautou; Swapan K Ray; Babak Razani; Bruce H Reed; Fulvio Reggiori; Markus Rehm; Andreas S Reichert; Theo Rein; David J Reiner; Eric Reits; Jun Ren; Xingcong Ren; Maurizio Renna; Jane Eb Reusch; Jose L Revuelta; Leticia Reyes; Alireza R Rezaie; Robert I Richards; Des R Richardson; Clémence Richetta; Michael A Riehle; Bertrand H Rihn; Yasuko Rikihisa; Brigit E Riley; Gerald Rimbach; Maria Rita Rippo; Konstantinos Ritis; Federica Rizzi; Elizete Rizzo; Peter J Roach; Jeffrey Robbins; Michel Roberge; Gabriela Roca; Maria Carmela Roccheri; Sonia Rocha; Cecilia Mp Rodrigues; Clara I Rodríguez; Santiago Rodriguez de Cordoba; Natalia Rodriguez-Muela; Jeroen Roelofs; Vladimir V Rogov; Troy T Rohn; Bärbel Rohrer; Davide Romanelli; Luigina Romani; Patricia Silvia Romano; M Isabel G Roncero; Jose Luis Rosa; Alicia Rosello; Kirill V Rosen; Philip Rosenstiel; Magdalena Rost-Roszkowska; Kevin A Roth; Gael Roué; Mustapha Rouis; Kasper M Rouschop; Daniel T Ruan; Diego Ruano; David C Rubinsztein; Edmund B Rucker; Assaf Rudich; Emil Rudolf; Ruediger Rudolf; Markus A Ruegg; Carmen Ruiz-Roldan; Avnika Ashok Ruparelia; Paola Rusmini; David W Russ; Gian Luigi Russo; Giuseppe Russo; Rossella Russo; Tor Erik Rusten; Victoria Ryabovol; Kevin M Ryan; Stefan W Ryter; David M Sabatini; Michael Sacher; Carsten Sachse; Michael N Sack; Junichi Sadoshima; Paul Saftig; Ronit Sagi-Eisenberg; Sumit Sahni; Pothana Saikumar; Tsunenori Saito; Tatsuya Saitoh; Koichi Sakakura; Machiko Sakoh-Nakatogawa; Yasuhito Sakuraba; María Salazar-Roa; Paolo Salomoni; Ashok K Saluja; Paul M Salvaterra; Rosa Salvioli; Afshin Samali; Anthony Mj Sanchez; José A Sánchez-Alcázar; Ricardo Sanchez-Prieto; Marco Sandri; Miguel A Sanjuan; Stefano Santaguida; Laura Santambrogio; Giorgio Santoni; Claudia Nunes Dos Santos; Shweta Saran; Marco Sardiello; Graeme Sargent; Pallabi Sarkar; Sovan Sarkar; Maria Rosa Sarrias; Minnie M Sarwal; Chihiro Sasakawa; Motoko Sasaki; Miklos Sass; Ken Sato; Miyuki Sato; Joseph Satriano; Niramol Savaraj; Svetlana Saveljeva; Liliana Schaefer; Ulrich E Schaible; Michael Scharl; Hermann M Schatzl; Randy Schekman; Wiep Scheper; Alfonso Schiavi; Hyman M Schipper; Hana Schmeisser; Jens Schmidt; Ingo Schmitz; Bianca E Schneider; E Marion Schneider; Jaime L Schneider; Eric A Schon; Miriam J Schönenberger; Axel H Schönthal; Daniel F Schorderet; Bernd Schröder; Sebastian Schuck; Ryan J Schulze; Melanie Schwarten; Thomas L Schwarz; Sebastiano Sciarretta; Kathleen Scotto; A Ivana Scovassi; Robert A Screaton; Mark Screen; Hugo Seca; Simon Sedej; Laura Segatori; Nava Segev; Per O Seglen; Jose M Seguí-Simarro; Juan Segura-Aguilar; Ekihiro Seki; Christian Sell; Iban Seiliez; Clay F Semenkovich; Gregg L Semenza; Utpal Sen; Andreas L Serra; Ana Serrano-Puebla; Hiromi Sesaki; Takao Setoguchi; Carmine Settembre; John J Shacka; Ayesha N Shajahan-Haq; Irving M Shapiro; Shweta Sharma; Hua She; C-K James Shen; Chiung-Chyi Shen; Han-Ming Shen; Sanbing Shen; Weili Shen; Rui Sheng; Xianyong Sheng; Zu-Hang Sheng; Trevor G Shepherd; Junyan Shi; Qiang Shi; Qinghua Shi; Yuguang Shi; Shusaku Shibutani; Kenichi Shibuya; Yoshihiro Shidoji; Jeng-Jer Shieh; Chwen-Ming Shih; Yohta Shimada; Shigeomi Shimizu; Dong Wook Shin; Mari L Shinohara; Michiko Shintani; Takahiro Shintani; Tetsuo Shioi; Ken Shirabe; Ronit Shiri-Sverdlov; Orian Shirihai; Gordon C Shore; Chih-Wen Shu; Deepak Shukla; Andriy A Sibirny; Valentina Sica; Christina J Sigurdson; Einar M Sigurdsson; Puran Singh Sijwali; Beata Sikorska; Wilian A Silveira; Sandrine Silvente-Poirot; Gary A Silverman; Jan Simak; Thomas Simmet; Anna Katharina Simon; Hans-Uwe Simon; Cristiano Simone; Matias Simons; Anne Simonsen; Rajat Singh; Shivendra V Singh; Shrawan K Singh; Debasish Sinha; Sangita Sinha; Frank A Sinicrope; Agnieszka Sirko; Kapil Sirohi; Balindiwe Jn Sishi; Annie Sittler; Parco M Siu; Efthimios Sivridis; Anna Skwarska; Ruth Slack; Iva Slaninová; Nikolai Slavov; Soraya S Smaili; Keiran Sm Smalley; Duncan R Smith; Stefaan J Soenen; Scott A Soleimanpour; Anita Solhaug; Kumaravel Somasundaram; Jin H Son; Avinash Sonawane; Chunjuan Song; Fuyong Song; Hyun Kyu Song; Ju-Xian Song; Wei Song; Kai Y Soo; Anil K Sood; Tuck Wah Soong; Virawudh Soontornniyomkij; Maurizio Sorice; Federica Sotgia; David R Soto-Pantoja; Areechun Sotthibundhu; Maria João Sousa; Herman P Spaink; Paul N Span; Anne Spang; Janet D Sparks; Peter G Speck; Stephen A Spector; Claudia D Spies; Wolfdieter Springer; Daret St Clair; Alessandra Stacchiotti; Bart Staels; Michael T Stang; Daniel T Starczynowski; Petro Starokadomskyy; Clemens Steegborn; John W Steele; Leonidas Stefanis; Joan Steffan; Christine M Stellrecht; Harald Stenmark; Tomasz M Stepkowski; Stęphan T Stern; Craig Stevens; Brent R Stockwell; Veronika Stoka; Zuzana Storchova; Björn Stork; Vassilis Stratoulias; Dimitrios J Stravopodis; Pavel Strnad; Anne Marie Strohecker; Anna-Lena Ström; Per Stromhaug; Jiri Stulik; Yu-Xiong Su; Zhaoliang Su; Carlos S Subauste; Srinivasa Subramaniam; Carolyn M Sue; Sang Won Suh; Xinbing Sui; Supawadee Sukseree; David Sulzer; Fang-Lin Sun; Jiaren Sun; Jun Sun; Shi-Yong Sun; Yang Sun; Yi Sun; Yingjie Sun; Vinod Sundaramoorthy; Joseph Sung; Hidekazu Suzuki; Kuninori Suzuki; Naoki Suzuki; Tadashi Suzuki; Yuichiro J Suzuki; Michele S Swanson; Charles Swanton; Karl Swärd; Ghanshyam Swarup; Sean T Sweeney; Paul W Sylvester; Zsuzsanna Szatmari; Eva Szegezdi; Peter W Szlosarek; Heinrich Taegtmeyer; Marco Tafani; Emmanuel Taillebourg; Stephen Wg Tait; Krisztina Takacs-Vellai; Yoshinori Takahashi; Szabolcs Takáts; Genzou Takemura; Nagio Takigawa; Nicholas J Talbot; Elena Tamagno; Jerome Tamburini; Cai-Ping Tan; Lan Tan; Mei Lan Tan; Ming Tan; Yee-Joo Tan; Keiji Tanaka; Masaki Tanaka; Daolin Tang; Dingzhong Tang; Guomei Tang; Isei Tanida; Kunikazu Tanji; Bakhos A Tannous; Jose A Tapia; Inmaculada Tasset-Cuevas; Marc Tatar; Iman Tavassoly; Nektarios Tavernarakis; Allen Taylor; Graham S Taylor; Gregory A Taylor; J Paul Taylor; Mark J Taylor; Elena V Tchetina; Andrew R Tee; Fatima Teixeira-Clerc; Sucheta Telang; Tewin Tencomnao; Ba-Bie Teng; Ru-Jeng Teng; Faraj Terro; Gianluca Tettamanti; Arianne L Theiss; Anne E Theron; Kelly Jean Thomas; Marcos P Thomé; Paul G Thomes; Andrew Thorburn; Jeremy Thorner; Thomas Thum; Michael Thumm; Teresa Lm Thurston; Ling Tian; Andreas Till; Jenny Pan-Yun Ting; Vladimir I Titorenko; Lilach Toker; Stefano Toldo; Sharon A Tooze; Ivan Topisirovic; Maria Lyngaas Torgersen; Liliana Torosantucci; Alicia Torriglia; Maria Rosaria Torrisi; Cathy Tournier; Roberto Towns; Vladimir Trajkovic; Leonardo H Travassos; Gemma Triola; Durga Nand Tripathi; Daniela Trisciuoglio; Rodrigo Troncoso; Ioannis P Trougakos; Anita C Truttmann; Kuen-Jer Tsai; Mario P Tschan; Yi-Hsin Tseng; Takayuki Tsukuba; Allan Tsung; Andrey S Tsvetkov; Shuiping Tu; Hsing-Yu Tuan; Marco Tucci; David A Tumbarello; Boris Turk; Vito Turk; Robin Fb Turner; Anders A Tveita; Suresh C Tyagi; Makoto Ubukata; Yasuo Uchiyama; Andrej Udelnow; Takashi Ueno; Midori Umekawa; Rika Umemiya-Shirafuji; Benjamin R Underwood; Christian Ungermann; Rodrigo P Ureshino; Ryo Ushioda; Vladimir N Uversky; Néstor L Uzcátegui; Thomas Vaccari; Maria I Vaccaro; Libuše Váchová; Helin Vakifahmetoglu-Norberg; Rut Valdor; Enza Maria Valente; Francois Vallette; Angela M Valverde; Greet Van den Berghe; Ludo Van Den Bosch; Gijs R van den Brink; F Gisou van der Goot; Ida J van der Klei; Luc Jw van der Laan; Wouter G van Doorn; Marjolein van Egmond; Kenneth L van Golen; Luc Van Kaer; Menno van Lookeren Campagne; Peter Vandenabeele; Wim Vandenberghe; Ilse Vanhorebeek; Isabel Varela-Nieto; M Helena Vasconcelos; Radovan Vasko; Demetrios G Vavvas; Ignacio Vega-Naredo; Guillermo Velasco; Athanassios D Velentzas; Panagiotis D Velentzas; Tibor Vellai; Edo Vellenga; Mikkel Holm Vendelbo; Kartik Venkatachalam; Natascia Ventura; Salvador Ventura; Patrícia St Veras; Mireille Verdier; Beata G Vertessy; Andrea Viale; Michel Vidal; Helena L A Vieira; Richard D Vierstra; Nadarajah Vigneswaran; Neeraj Vij; Miquel Vila; Margarita Villar; Victor H Villar; Joan Villarroya; Cécile Vindis; Giampietro Viola; Maria Teresa Viscomi; Giovanni Vitale; Dan T Vogl; Olga V Voitsekhovskaja; Clarissa von Haefen; Karin von Schwarzenberg; Daniel E Voth; Valérie Vouret-Craviari; Kristina Vuori; Jatin M Vyas; Christian Waeber; Cheryl Lyn Walker; Mark J Walker; Jochen Walter; Lei Wan; Xiangbo Wan; Bo Wang; Caihong Wang; Chao-Yung Wang; Chengshu Wang; Chenran Wang; Chuangui Wang; Dong Wang; Fen Wang; Fuxin Wang; Guanghui Wang; Hai-Jie Wang; Haichao Wang; Hong-Gang Wang; Hongmin Wang; Horng-Dar Wang; Jing Wang; Junjun Wang; Mei Wang; Mei-Qing Wang; Pei-Yu Wang; Peng Wang; Richard C Wang; Shuo Wang; Ting-Fang Wang; Xian Wang; Xiao-Jia Wang; Xiao-Wei Wang; Xin Wang; Xuejun Wang; Yan Wang; Yanming Wang; Ying Wang; Ying-Jan Wang; Yipeng Wang; Yu Wang; Yu Tian Wang; Yuqing Wang; Zhi-Nong Wang; Pablo Wappner; Carl Ward; Diane McVey Ward; Gary Warnes; Hirotaka Watada; Yoshihisa Watanabe; Kei Watase; Timothy E Weaver; Colin D Weekes; Jiwu Wei; Thomas Weide; Conrad C Weihl; Günther Weindl; Simone Nardin Weis; Longping Wen; Xin Wen; Yunfei Wen; Benedikt Westermann; Cornelia M Weyand; Anthony R White; Eileen White; J Lindsay Whitton; Alexander J Whitworth; Joëlle Wiels; Franziska Wild; Manon E Wildenberg; Tom Wileman; Deepti Srinivas Wilkinson; Simon Wilkinson; Dieter Willbold; Chris Williams; Katherine Williams; Peter R Williamson; Konstanze F Winklhofer; Steven S Witkin; Stephanie E Wohlgemuth; Thomas Wollert; Ernst J Wolvetang; Esther Wong; G William Wong; Richard W Wong; Vincent Kam Wai Wong; Elizabeth A Woodcock; Karen L Wright; Chunlai Wu; Defeng Wu; Gen Sheng Wu; Jian Wu; Junfang Wu; Mian Wu; Min Wu; Shengzhou Wu; William Kk Wu; Yaohua Wu; Zhenlong Wu; Cristina Pr Xavier; Ramnik J Xavier; Gui-Xian Xia; Tian Xia; Weiliang Xia; Yong Xia; Hengyi Xiao; Jian Xiao; Shi Xiao; Wuhan Xiao; Chuan-Ming Xie; Zhiping Xie; Zhonglin Xie; Maria Xilouri; Yuyan Xiong; Chuanshan Xu; Congfeng Xu; Feng Xu; Haoxing Xu; Hongwei Xu; Jian Xu; Jianzhen Xu; Jinxian Xu; Liang Xu; Xiaolei Xu; Yangqing Xu; Ye Xu; Zhi-Xiang Xu; Ziheng Xu; Yu Xue; Takahiro Yamada; Ai Yamamoto; Koji Yamanaka; Shunhei Yamashina; Shigeko Yamashiro; Bing Yan; Bo Yan; Xianghua Yan; Zhen Yan; Yasuo Yanagi; Dun-Sheng Yang; Jin-Ming Yang; Liu Yang; Minghua Yang; Pei-Ming Yang; Peixin Yang; Qian Yang; Wannian Yang; Wei Yuan Yang; Xuesong Yang; Yi Yang; Ying Yang; Zhifen Yang; Zhihong Yang; Meng-Chao Yao; Pamela J Yao; Xiaofeng Yao; Zhenyu Yao; Zhiyuan Yao; Linda S Yasui; Mingxiang Ye; Barry Yedvobnick; Behzad Yeganeh; Elizabeth S Yeh; Patricia L Yeyati; Fan Yi; Long Yi; Xiao-Ming Yin; Calvin K Yip; Yeong-Min Yoo; Young Hyun Yoo; Seung-Yong Yoon; Ken-Ichi Yoshida; Tamotsu Yoshimori; Ken H Young; Huixin Yu; Jane J Yu; Jin-Tai Yu; Jun Yu; Li Yu; W Haung Yu; Xiao-Fang Yu; Zhengping Yu; Junying Yuan; Zhi-Min Yuan; Beatrice Yjt Yue; Jianbo Yue; Zhenyu Yue; David N Zacks; Eldad Zacksenhaus; Nadia Zaffaroni; Tania Zaglia; Zahra Zakeri; Vincent Zecchini; Jinsheng Zeng; Min Zeng; Qi Zeng; Antonis S Zervos; Donna D Zhang; Fan Zhang; Guo Zhang; Guo-Chang Zhang; Hao Zhang; Hong Zhang; Hong Zhang; Hongbing Zhang; Jian Zhang; Jian Zhang; Jiangwei Zhang; Jianhua Zhang; Jing-Pu Zhang; Li Zhang; Lin Zhang; Lin Zhang; Long Zhang; Ming-Yong Zhang; Xiangnan Zhang; Xu Dong Zhang; Yan Zhang; Yang Zhang; Yanjin Zhang; Yingmei Zhang; Yunjiao Zhang; Mei Zhao; Wei-Li Zhao; Xiaonan Zhao; Yan G Zhao; Ying Zhao; Yongchao Zhao; Yu-Xia Zhao; Zhendong Zhao; Zhizhuang J Zhao; Dexian Zheng; Xi-Long Zheng; Xiaoxiang Zheng; Boris Zhivotovsky; Qing Zhong; Guang-Zhou Zhou; Guofei Zhou; Huiping Zhou; Shu-Feng Zhou; Xu-Jie Zhou; Hongxin Zhu; Hua Zhu; Wei-Guo Zhu; Wenhua Zhu; Xiao-Feng Zhu; Yuhua Zhu; Shi-Mei Zhuang; Xiaohong Zhuang; Elio Ziparo; Christos E Zois; Teresa Zoladek; Wei-Xing Zong; Antonio Zorzano; Susu M Zughaier
Journal:  Autophagy       Date:  2016       Impact factor: 16.016

Review 10.  HDAC6 and ovarian cancer.

Authors:  Joshua Haakenson; Xiaohong Zhang
Journal:  Int J Mol Sci       Date:  2013-05-02       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.